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Resumo 
	  
	  	   A tuberculose (TB) é uma doença infeciosa com uma elevada incidência e 
prevalência em todo o mundo, especialmente nos países subdesenvolvidos. A TB é 
causada pela bactéria, Mycobacterium tuberculosis (MTb), sendo a segunda doença 
infeciosa mais prevalente da humanidade, logo a seguir à infeção pelo vírus da 
imunodeficiência humana (VIH). Progressos significativos têm sido alcançados ao longo 
dos últimos anos, no que concerne à redução da incidência, prevalência e número de 
mortes associada à doença, sendo objetivo da Organização Mundial de Saúde (OMS) 
erradicar a TB até 2050. No entanto, a emergência de estirpes multirresistentes ao 
arsenal terapêutico existente, pode colocar em causa este ambicioso mas factível 
objetivo da OMS. De acordo com o que foi referido sobre a persistência, número de 
mortes associado à TB bem como a emergência de estirpes multirresistentes, torna-se 
imperativo que surjam novos fármacos mais eficazes no combate a esta doença. A 
abordagem mais imediata consiste na alteração da estrutura química dos antibióticos já 
existentes e o melhoramento das suas propriedades farmacocinéticas e 
farmacodinâmicas. Nesse sentido, nesta tese foram estudados novos análogos sintéticos 
da rifabutina (RFB), nomeadamente a N’-acetil-rifabutina (RFB2) e a N'-butanoil-rifabutina 
(RFB3). A RFB foi um dos últimos antibióticos para o tratamento da TB a ser introduzido 
no mercado, em 1992, sendo a sua extrema eficácia em grande parte devido às suas 
características anfifílicas e capacidade de atravessar membranas biológicas. Os testes in 
vitro e in vivo demonstraram que a RFB2 constitui um candidato promissor e com 
potencial para chegar ao mercado. A RFB3 é um composto de síntese intermediário entre 
a RFB2 e outro derivado (com um grupo acilo maior, nomeadamente o undecanoilo) que 
também demonstrou ser promissor, mas que por uma questão de reduzida solubilidade 
em soluções aquososas, não foi estudado durante esta tese. A RFB para que exerça a 
sua ação farmacológica necessita atravessar as membranas das mucosas 
gastrointestinais, membranas plasmáticas e a membrana bacteriana de forma a alcançar 
a RNA polimerase, situada no interior da célula bacteriana. Assim, após uma 
administração por via oral, este antibiótico percorre uma trajetória extremamente 
complexa que envolve membranas biológicas, alcançando locais de difícil acesso onde a 
bactéria se encontra alojada, como se verifica no caso da TB pulmonar, em que a 
bactéria se localiza marioritariamente no interior dos macrófagos alveolares, 
encontrando-se estes por vezes envolvidos em estruturas como os granulomas.  
A primeira abordagem no estudo de interação fármaco-membrana foi a 
determinação do coeficiente de partição lípido/água por espectrofotometria derivativa de 
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ultravioleta-visível (UV/Vis) com modelos de surfactante pulmonar e de membrana 
plasmática eucarionte e procarionte. A previsão da localização da RFB e análogos a nível 
da bicamada dos modelos membranares foi efetuada por estudos de desativação de 
fluorescência. Através dos estudos de anisotropia de fluorescência em estado 
estacionário, espectroscopia de correlação fotónica e de difração de raios-X foi possível 
estudar a influência dos compostos antimicobacterianos a nível das propriedades 
biofísicas dos modelos membranares. Para além dos modelos tridimensionais em 
bicamada, foram também utilizados modelos bidimensionais em monocamada para 
mimetizar as membranas biológicas. As isotérmicas de Langmuir aplicadas a estes 
modelos permitiram o estudo da influência dos compostos antimicobacterianos nas 
propriedades das monocamadas, como a pressão lateral, área de superfície, efeitos a 
nível das transições, pressão de colapso e compressibilidade. Adicionalmente, foi 
possível a visualização das monocamadas por microscopia do ângulo de Brewster, 
permintindo o estudo da influência dos compostos nas monocamadas em termos de 
alteração da fluidez e influência sobre o tamanho e formato dos domínios lipídicos. A 
espectroscopia de absorção-reflexão de infravermelhos permitiu o estudo da influência da 
RFB e análogos na estrutura dos modelos membranares utilizados. A espectroscopia de 
reflexão UV-Vis permitiu a confirmação da presença do fármaco a nível da interface e da 
variação da sua concentração com a compressão/descompressão da monocamada. 
Foram ainda aplicados estudos de simulação computacional de forma a confirmar a 
hipótese inicialmente colocada de que uma forte ligação ocorre entre o fármaco e a 
região polar dos fosfolípidos do surfactante pulmonar. 
 Os resultados obtidos permitiram inferir que a RFB e análogos interagem com as 
membranas eucariontes e procariontes de forma diferencial. Assim, estes compostos 
antimicobacterianos possuem uma maior partilha para os modelos membranares 
procariontes e alteram as suas propriedades biofísicas de uma forma mais pronunciada. 
A interação com o surfactante pulmonar ocorre através da formação de um complexo de 
inclusão entre a RFB e os grupos polar dos fosfolipídios, o que poderá justificar a 
acumulação deste fármaco a nível do pulmão. Os análogos da RFB interagem com as 
membranas plasmáticas eucariontes de forma mais marcada do que a RFB. Assim, os 
análogos da RFB deverão possuir uma maior biodisponibilidade, o que poderá 
eventualmente permitir reduzir o número de tomas, mas também ser responsável por 
efeitos secundários mais pronunciados, sendo por isso necessário estudos futuros para 
assegurar que estas novas moléculas promissoras possam chegar ao mercado. 	  
Palavras-chave: biofísica, interações fármaco-membrana; modelos membranares; 
rifabutina; tuberculose. 
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Abstract 
	  
	  
Tuberculosis (TB) is an infectious disease with a high worldwide incidence and 
prevalence, especially in the developing countries. TB is caused by the bacterium MTb, 
being the second most common infectious disease affecting the humankind, after the 
human immunodeficiency virus (HIV) infection. Significant progresses over the last years 
have been made to reduce the incidence, prevalence and number of deaths caused by 
the disease, being the main goal of the World Health Organization (WHO) the eradication 
of TB until 2050. Nevertheless, the emergence of multidrug resistant (MDR) strains may 
undermine the ambitious but praticable objective of the WHO. Therefore, and according 
the above-mentioned concerns about TB persistence, mortality and emergence of MDR 
strains, new and more effective drugs are urgently needed. The most obvious approach is 
the alteration of the chemical structure of old antibiotic families and their improvement in 
terms of their pharmacokinetics and pharmacodynamics properties. In this context, two 
novel synthetized rifabutin (RFB) analogs were studied in this thesis, namely, N’-acetyl-
rifabutin (RFB2) and N’-butanoyl-rifabutin (RFB3). RFB was one of the last antibiotics 
introduced in the market for the treatment of TB (in 1992), being extremely efficient, in part 
due to its amphiphilic properties and ability to cross the biologic membranes. RFB2 was 
tested in vitro and in vivo and demonstrated to be a promising candidate with potential to 
reach the market. RFB3 is an intermediate synthetic compound between RFB2 and other 
analog (with a higher acyl group, undecanoyl), which was demonstrated to be a promise 
compound but which was abandoned since it has a poor solubility in aqueous solutions. In 
order to exert its pharmacological effect and reach the intracellular RNA polymerase, RFB 
needs to cross the biological membranes, including gastrointestinal tract, plasmatic 
human and bacterial membranes. Thus, after the oral intake, RFB follows a complex 
course, in order to reach the sites where the bacterium is located, sometimes places of 
difficult access as in the case of the pulmonary TB, where the bacteria is located inside 
the alveolar macrophages (AMs), which in some cases are inside the granulomas. 
The first approach to the study of the drug-membrane interactions was the 
determination of the partition coefficient lipid/water by UV/Vis derivative 
spectrophotometry, using eukaryotic plasma and pulmonary surfactant (PS) membrane 
models, and prokaryotic plasma membrane models. The prevision of the location of RFB 
and analogs within the lipid bilayer of the membrane models was assessed using 
fluorescence quenching. The steady-state anisotropy, dynamic light scattering and x-ray 
diffraction studies allowed to study the influence of the antimycobacterial compounds on 
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the biophysical parameters of the membrane models. Besides the three-dimensional (i.e. 
bilayers), two-dimensional (i.e. Langmuir monolayers) models were used to mimic the 
biological membranes.  The Langmuir isotherms applied to the mentioned membrane 
models allowed to study the influence of the antimycobacterial compounds on the 
monolayers properties, such as the lateral pressure, surface area, transitions, collapse 
pressure and compressibility. Additionally, the visualization of the monolayers was 
possible by the Brewster angle microscopy (BAM), which allowed to study the influence of 
the antimycobacterial compounds in the fluidity of the monolayers as well as in the 
shape/size of the lipid domains of the monolayers. The infrared absorption-reflection 
spectroscopy (IRRAS) allowed the study of the influence of RFB and analogs on the 
structure of the chosen membrane models. The UV-Vis reflection spectroscopy permitted 
the confirmation of the drug’s presence at the air-water interface and the variation of its 
concentration with the monolayer compression/decompression. Computational simulation 
studies were also applied and corroborate the initial hypothesis of a strong binding 
between the drug and the polar head groups of the phospholipids of the PS. 
The results obtained allowed to infer that RFB and its analogs interact by a 
differential way with the eukaryotic and prokaryotic membranes. Thus, these compounds 
possess a higher partition to the prokaryotic membrane models, having a more 
pronounced effect on its biophysical properties. The interaction with the PS occurs with 
the formation of an inclusion complex between RFB and the polar groups of the 
phospholipids, which may be related with the drug’s accumulation in the lungs. The 
analogs of RFB interact with the eukaryotic plasma membranes more markedly than RFB. 
Thus, the analogs seem to have a higher bioavailability, which may allow a dosage 
reduction, although probably with more pronounced side effects, being further studies 
needed to ensure that these novel promising molecules may reach the market. 
 
 
 
 
 
 
 
 
Keywords: biophysics, drug-membrane interactions; membrane models; rifabutin; 
tuberculosis. 
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Chapter I 
 
Introduction 
 
1. Observations Beyond the Thesis 
	  
	  
TB is still a major infectious disease that affects the humankind. The emergence of 
multidrug resistant strains is one of the main concerns associated with the TB 
management. In this regard, new antibiotic molecules are needed, being the re-
engineering of old drug families molecules the most immediate way to their obtention. 
Nevertheless, the drug’s mechanism of action must be fully understood since the design 
of drugs taking in consideration solely the pharmacologic target is not a guaranty of 
success. The ryfamicins, which inhibit the bacterial RNA polymerase include among 
others, RFB and rifampicin (RIF). The ryfamicins are a very successful class of drugs in 
the TB treatment, being RIF a first-line drug commonly used throughout the entire TB 
treatment. RFB, which was one of the last antibiotics to TB treatment brought to the 
market, is generally used as a second-line drug. Nevertheless, RFB is at least as effective 
and safe as RIF, presenting however a much higher financial cost associated. RFB is 
used as a first choice in cases where resistance to the RIF occurs, as well in the case of 
co-infected HIV/TB patients, since it is less prone to interact with the enzymes that 
metabolize the antiretroviral drugs. The accepted mechanism of action of RFB involves 
the binding to the β-subunit of the RNA polymerase, causing the inhibition of the RNA 
transcription and consequently the inhibition of the bacterial protein synthesis. The binding 
constant for prokaryotic RNA polymerases is 10000-fold higher than those for eukaryotic 
enzymes, which in part might explain the higher selectivity of this drug to the bacteria. 
However, a lack of correlation exists between the RFB inhibitory activity on the RNA 
polymerase and the antibiotic efficacy. In fact, the drug’s penetration through the bacteria 
cells explains the higher activity against Gram-positive compared to the Gram-negative 
despite the quite similar RNA polymerase inhibitory activities. Therefore, the efficiency of 
the interactions of the antibiotics with the membranes constitutes one of the most 
important pharmacological features, playing an essential role on its biological activity, and 
should be accounted in order to understand their full mechanism of action. RFB has an 
intracellular target, and hence it must pass across phospholipid bilayers to reach the RNA 
polymerase and elicit its pharmacological effect. Since RFB has a high lipophilicity, the 
passive diffusion is probably the most relevant process of the RFB’s permeation through 
the membranes. The plasma concentrations achieved by RFB do not reflect the much 
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higher concentrations that can be reached in target organs and infected cells. In fact, RFB 
penetrates well into infected cells (i.e. macrophages) and in organs as the lungs the 
concentrations are at levels six times higher compared with the plasma concentrations. 
On the other hand, RFB, despite being well-tolerated, presents some of the side effects 
including uveitis, rash, nausea, vomiting, neutropenia, anemia, discoloration of the skin 
and body fluids (tears, saliva, urine and perspiration) and, rarely, clinically important 
impairment of the liver function. Indeed, the mentioned side effects seem to be related 
with the RFB tropism and affinity to the membranes, including the ability to reach to 
specialized membranes of the human body (e.g. epiretinal, stractum corneum 
membranes) and the capacity to diffuse through the human body, crossing several 
biological membranes, promoting the discoloration of body fluids (e.g. tears, perspiration, 
urine and saliva). In addition, the lipids of the MTb (i.e. mycolic acids (MAs) and cord 
factor (TDM)) are recognized to be responsible for the impairment and dysfunction of the 
PS membrane. Moreover, the mentioned lipids change the compressibility of the PS 
causing an impairment of its normal function and thus it is appealable to study the effect of 
drugs on the PS membrane models and understand if the drugs have any protective 
effect.  
In this thesis, RFB was used as the lead compound for the new promising 
molecules against TB. Therefore, studies of the RFB2 and RFB3-membrane interactions 
are needed, since antibiotic–membrane interactions play a crucial role for the 
understanding of the drugs bioavailability, the drugs entrance into the cellular 
compartments, and the drugs-induced toxicity. In addition, a relationship between the 
chemical structure of the molecules and the corresponding effect in the plasma membrane 
will be useful. The founded correlation will give useful indications for understanding the 
influence of different structural interdependencies between antimycobacterial compound’s 
chemical composition and antimycobacterial compound’s expected effects, which 
ultimately may permit the development of more effective and less toxic anti-TB drugs. 
Moreover, the knowledge about drug-membrane biophysical interactions is of utmost 
importance for the rational development of new drugs as well as for the development of 
lipid-based nano-carriers (e.g. lipid nanoparticles and liposomes) as drug delivery systems 
for these antimycobacterial compounds. 
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2. Objectives of The thesis 
 
	  
Three main objectives are undertaken in this thesis, being interlinked: 
 
- The first objective is to get a more complete picture about the mechanism of 
action of RFB. Nowadays, the mechanism of action of RFB and several other drugs is 
viewed as the binding to a specific target (e.g. enzyme, receptor). Notwithstanding, since 
the oral intake of RFB, the primary barriers that the drug encountered by the drug are in 
fact the biological membranes. In addition, to reach the RNA polymerase RFB has to 
cross trough several different types of membranes. The idea beyond the selective binding 
to the bacterial RNA polymerase is highly simplistic and has several weak points. Thus, 
the question related with the higher efficacy in Gram-positive than in Gram-negative, 
despite the similar binding activity to the RNA polymerase remains unsolved. Moreover, it 
is well known that part of the success of RFB is due to its bioaccumulation in the lungs 
and in the infected cells, being the mechanism beneath this an open question. In addition, 
the toxic effects of this drug are not fully understood and do not seem to be related with 
the binding to the RNA polymerase that also exist in the human cells.  
 
- The second objective is devoted to the study of RFB2 and RFB3-membrane 
interactions in order to appreciate if the RFB analogs have favorable pharmacokinetic 
properties to reach the market. In this regard, a relationship between the chemical 
structure of the antimycobacterial compounds and their activity on the membranes was 
also established. This may be useful to the design of more effective drugs with less side 
effects, since a rational drug design will certainly benefit of the knowledge beyond the 
interactions with the membranes at the molecule level. 
	  
- The third objective is to get a higher knowledge regarding the MTb infection and 
the TB disease. In this context, for the first time a biophysical approach applied to TB was 
developed, which may contribute to a higher knowledge related with the MTb infection 
and TB disease. Despite a physiopatologic effect, the lipids present in the MTb cell wall 
seem to be related with the bacteria access to the target (i.e. AMs). Moreover, the effect 
of the drug at the PS level in the presence of MTb lipids was also studied in order to 
understand the putative protective effect of the drug, from the effects of the lipids present 
in the MTb cell wall, at the PS membrane.  
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3. Structure of the Thesis 
 
 This thesis is divided into five chapters:  
 
Chapter I: Introduction. This chapter includes the introduction of the thesis, which 
comprises the motivation and the main objectives. Moreover, it covers a general 
description of the other chapters, namely their organization and structure. 
 
Chapter II: Theoretical Background. A full description of the theoretical concepts 
approached in this thesis is provided in this chapter. Therefore, the concepts considered 
essential to understand the results and the conclusions are scrutinized, including 
predominatly two main fields, the TB and the biomembranes. Thus, the chapter starts with 
the description of the infectious disease TB, the epidemiology and etiology of TB, how the 
transmission occurs, the physiopathology concepts, the main clinical manifestations of the 
disease, the diagnosis methods, the vaccines and the treatment for TB. In the treatment 
are included the chemotherapy and the drugs with interest for TB, including RFB and its 
analogs. Moreover, the concepts regarding the biological cell membranes are addressed, 
including their function, structure, the molecular composition of the eukaryotic, prokaryotic 
plasma membranes and PS, as well as the lamellar phase transition of the membrane 
models used to mimic the former membranes. 
 
Chapter III: Methods to Evaluate the Antimycobacterial Compounds-Membrane 
Interactions. In this chapter, the biophysical techniques used during this thesis are 
presented. The methods applied to the drug-membrane interaction studies were: UV-Vis 
Derivate Spectrophotometry to calculate the partition coefficient of the antimycobacterial 
compounds; Fluorescence Quenching to study the location of the antimycobacterial 
compounds within the lipid bilayers of the membrane models; Steady-state Anisotropy, X-
ray studies and Dynamic Light Scattering to study the influence of the antimycobacterial 
compounds on the biophysical parameters of the membrane models. Moreover, Langmuir 
Isotherms, Brewster Angle Microscopy, Polarization Modulation Infrared Reflection-
Absorption Spectroscopy, Reflection UV-Vis Spectroscopy and Computational 
Simulations were carried out in the monolayers as membrane model systems in order to 
understand the influence of RFB and analogs on the structure and lipid organization. 
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Chapter IV: Progress Beyond the State-of-the Art. This chapter is focused exclusively 
in the manuscripts that this thesis originated, namely: 
 
1 – Liposomes as drug delivery systems for the treatment of TB.  
Pinheiro M, Lúcio M, Lima J, Reis S. Nanomedicine. 2011; 6(8):1413-28. 
doi:10.2217/nnm.11.122. 
 
2 – Molecular interaction of Rifabutin on model lung surfactant monolayers. 
Pinheiro M, Lúcio M, Reis S, Lima JLFC, Caio JM, Moiteiro C, et al. The Journal of 
Physical Chemistry B. 2012;116(38):11635–45. doi: 10.1021/jp303725j. 
 
3 – Interplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant 
membrane: a biophysical approach to disease. 
Pinheiro M, Giner-Casares J, Lúcio L, Caio J, Moiteiro C, Lima L, et al. 
BBA:Biomembranes. 2013;1828:896–905. doi: 10.1016/j.bbamem.2012.09.015. 
 
4 – Differential interactions of rifabutin with human and bacterial membranes: implication 
for its therapeutic and toxic effects. 
Pinheiro M, Arêde M, Nunes C, Caio JM, Moiteiro C, Lúcio M, et al. Journal of Medicinal 
Chemistry. 2013;56(2):417–26. doi: 10.1021/jm301116j. 
 
5 – Drug-membrane interaction studies applied to N'-acetyl-rifabutin. 
Pinheiro M, Arêde M, Caio JM, Moiteiro C, Lúcio M, Reis S. European Journal of 
Pharmaceutics and Biopharmaceutics. 2013; doi: 10.1016/j.ejpb.2013.02.015. 
 
6 – Effects of a novel antimycobacterial compound on the biophysical properties of a 
pulmonary surfactant model membrane. 
Pinheiro M, Arêde M, Giner-Casares JJ, Nunes C, Caio JM, Moiteiro C, et al. International 
Journal of Pharmaceutics. 2013; 450(1-2):268-77. doi: 10.1016/j.ijpharm.2013.03.062. 
 
7 – Evaluation of the structure-activity relationship of rifabutin and analogs: a drug-
membrane study. 
Pinheiro M, Leite-Leite P, Arêde M, Nunes C, Caio JM, Moiteiro C, et al. ChemPhysChem. 
2013; doi: 10.1002/cphc.201300262. 
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8 – The Influence of Rifabutin on Human and Bacterial Membrane Models: Implications for 
Its Mechanism of Action. 
Pinheiro M, Nunes C, Caio JM, Moiteiro C, Lúcio M, Brezesinski G, et al. The Journal of 
Physical Chemistry B. 2013; 117(20):6187-93. doi: 10.1021/jp403073v.  
 
9 – Interactions of N'-acetyl-rifabutin and N'-butanoyl-rifabutin with lipid bilayers: A 
synchrotron X-ray study. 
Pinheiro M, Nunes C, Caio JM, Moiteiro C, Brezesinski G, Reis S. International Journal of 
Pharmaceutics. 2013; 10;453(2):560-8; doi: 10.1016/j.ijpharm.2013.06.018. 
 
Chapter V: Conclusions. In this chapter, the main concluding remarks based on the 
findings of the studies presented in this thesis are described. Furthermore, the limitations 
of the experimental studies and future perspectives for further research are also 
presented. 
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CHAPTER II 
 
Theoretical Background 
 
1. Tuberculosis 
 
"If the importance of a disease for mankind is measured by the number of fatalities 
it causes, then tuberculosis must be considered much more important than those most 
feared infectious diseases, plague, cholera and the like. One in seven of all human beings 
dies from tuberculosis. If one only considers the productive middle-age groups, 
tuberculosis carries away one third, and often more.” [1] 
Robert Koch  
(lecture on the evening of March 24 in 1882, about his discovery of Mycobacterium 
tuberculosis) 
	  
	  
Tuberculosis (TB) is an ancient disease, first described by Hippocrates (400 B.C.) 
in his works ‘‘Of the Epidemics’’ and posterior documented by Claudius Galen during the 
Roman Empire period [2]. The etiologic agent of TB, Mycobacterium tuberculosis (MTb) 
(Figure 1) was first described by Robert Koch in 1882 [3]. In fact, TB is a disease rich in 
paradoxes, being one of the first diseases for which the causative agent was identified 
(i.e. MTb), and one of the earliest for which a vaccine and a diagnostic method were 
developed. Anti-TB drugs effective against MTb are also available for more than a half 
century [4]. Despite the above-mentioned, TB is still a leading cause of death among 
infectious diseases [5]. During the Industrial Revolution, TB reached epidemic levels in 
Europe, being responsible for one in four deaths from the sixteenth to eighteenth 
centuries [2]. Nowadays, TB is still a major worldwide health concern, being the cause of 
a serious health condition among millions of people every year, ranking as the second 
leading cause of death from an infectious disease worldwide, after the human 
immunodeficiency virus [6-8]. Indeed, somewhere in the world almost 20 people develop 
TB and four people die from the disease each minute [9].  
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Figure 1. Scanning electron microscope image of MTb. Adapted from [10]. 
 
1.1. Epidemiology  
	  
MTb infection currently affects around a third of the world’s population 
(approximately 2 billion of people). With such a reservoir, the control of TB seems to be a 
difficult task to achieve [11]. In most cases, the bacterium and the host establish an 
equilibrium, and thus infected individuals can remain asymptomatic for several decades, if 
not for their entire lifetime. However, about one-tenth of the infected individuals develop 
the disease [12].  Besides representing a severe health problem in developing countries, 
TB has become a renewed threat in the Western world since the mid 1980’s. In view of 
this situation, in 1993 the WHO declared TB as a global public health emergency [13]. 
Geographically, TB has more prevalence in Asia and Africa [7],[14]. In fact, countries as 
India and China account together for almost 40% of the world’s TB cases. About 60% of 
cases are in the South-East Asia and Western Pacific regions. The African Region has 
24% of the world’s cases, and the highest rates of cases and deaths per capita. In Europe 
there is an enormous disparity in the rates of TB between the western and eastern, being 
the rates of disease different between urban and non-urban settings [15]. In the particular 
case of Portugal, which is one of the most concerning in Europe, the incidence in 2012 
was of 2480 new cases, resulting in 117 deaths [16]. 
Worldwide, 3.7% of the new cases and 20% of the previously treated cases were 
estimated to have multidrug-resistant TB (MDR-TB). According to the WHO, 8.7 million 
cases of active TB emerge annually, resulting in 1.4 million deaths in 2011. Figure 2 
shows the regional incidences of TB. From the 8.7 million people who developed TB 
worldwide, 13% were HIV-positive. Globally in 2011, there were an estimated 630 000 
cases of MDR-TB. In addition, there were an estimated 0.5 million cases and 64 000 
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deaths among children in the same year. The number of notifications, which are 
mandatory, to the national TB control programs are roughly two thirds of the estimated 
total, being therefore major efforts needed to ensure that all the cases are notified to the 
regulatory authorities [7].  
  
Figure 2. Estimated TB incidence rates, 2011. Adapted from [7]. 
 
Progress towards a decrease in the TB burden has been made in the absolute TB 
cases and deaths. Thus, new cases of TB have been declining for several years and the 
mortality rate has decreased 41% since 1990 [13]. Notwithstanding, the significant 
progress that has been made to reduce the global impact of TB, the emergence of MDR-
TB (resistant to at least two main first-line anti-TB drugs, isoniazid and RIF) and 
extensively drug-resistant (XDR) (resistant to three or more second-line anti-TB drugs) 
threatens these advancements [17-18].  
The major goal of the WHO is to eradicate TB as a public health problem until 
2050 by reaching a global incidence of the disease to less than one case per million 
population [13]. This although possible, constitutes an ambitious goal to approach.	  To be 
achieved, this goal requires intensified efforts and more effective and affordable new 
technologies to prevent both infection and disease, and quick mechanisms to allow their 
worldwide introduction [19]. 
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1.2. Etiology 
 
The Mycobacterium tuberculosis complex comprises closely related species, 
which are the cause of TB in human and other animals including, MTb, Mycobacterium 
bovis, Mycobacterium africanum, Mycobacterium microti and Mycobacterium canetti [20-
21]. In humans, TB is primarily caused by MTb and Mycobacterium africanum, being the 
former species restricted to the West Africa. Both species are obligate human pathogens 
with limited survival outside of the human body and with no known animal reservoir. 
Mycobacterium bovis is a cattle pathogen, which may also affect the human. 
Nevertheless, Mycobacterium bovis infections in humans decreased markedly due to the 
introduction of milk pasteurization and meat-control practices [22]. Mycobacterium microti 
causes TB in small rodents like voles and its importance for TB in humans remained 
unclear. Mycobacterium canetti can also cause TB in humans, but only a restricted 
number of strains have been isolated so far [20].  
With the evolution of science and most specifically genetics, the point of view that 
TB had its origin in nonhuman animals has markedly changed. Actually, the most 
probable scenario strongly suggests that humans were responsible for the TB in the other 
animals and that TB seems to have its origin in Africa following the out-of-Africa 
migrations of modern humans [22-23]. 
1.3. Transmission  
 
TB infection is usually initiated by the entry of MTb in the respiratory system 
through aerosol droplets (Figure 3). Thus, people with active TB can infect many others by 
coughing, sneezing, spitting, or speaking [24]. 
 
 
 
 
 
 
 
 
 
 
Figure 3. TB transmission. 
Inhala&on(of(aerosol(droplets(
containing(MTb(by(coughing,(
sneezing,(spi:ng,(or(speaking(
of(an(infected(person(
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The association of TB with HIV infection has significantly exacerbated the situation 
in developed and developing nations [25]. HIV infection is the highest risk factor identified, 
so far, for the progression of latent tuberculosis to an active disease state, with co-infected 
people having a higher 5-15% risk of early development of active TB [26]. TB represents a 
major cause of death in HIV co-infected individuals [27-29]. Other conditions can also 
impair the human host defense, increasing the risk of TB reactivation, including other co-
infections (helminths, non-tuberculous mycobacteria, virus) and comorbidities as type-2 
diabetes. Latent MTb infection may also be reactivated following treatment with biological 
therapy, such as the tumor necrosis factor alpha (TNF-α)/interleukin (IL) 12/IL-23 
blockers, commonly used in inflammatory diseases such as rheumatoid arthritis, Crohn’s 
disease, psoriasis and others [30-32]. Additionally, poverty, malnutrition and indoor air 
pollution constitute etiological risk factors that affect the TB incidence and the treatment 
outcomes [31]. 
 
1.4. Physiopathology 
 
In the lungs the facultative intracellular parasite MTb is non-specifically 
phagocytized, mainly by the alveolar macrophages (AMs), within which is able to survive 
and multiply [33-34]. Other phagocytic cells such as the local dendritic cells (DCs) and 
interstitial macrophages may also participate in the uptake of the MTb bacilli. In addition, 
the bacilli can even enter through the bronchial epithelium [30]. Besides, the MTb places 
itself nearby the PS, which may suffer dysfunction when the lipids, of the extremely rich in 
lipids mycobacteria cell wall, are present at the air/water interface [35]. The main lipids 
implied in this pulmonary surfactant negative effect seem to be the MAs and TDM [35-37]. 
In comparison with other microorganisms, MTb has an unusual ability to delay the 
adaptive immune response for 2-3 weeks in humans and experimental animals (Figure 4) 
[38]. The MTb-infected cells fail to migrate from the infected lung focus to the local 
draining lymph nodes, where the T-cell are located. This delay allows the production of a 
significant mass of the bacilli before the adaptive immunity can develop sufficiently to 
control the infection [30]. 
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Figure 4. Delayed onset of adaptive immunity in TB (Right) compared with other infectious (Left). 
Adapted from [38]. 
 
Nevertheless, in most people the infection does not constitute a healthy problem because 
MTb have developed an extraordinary ability to live in balance with immune responses 
[39]. In fact, MTb has the extreme capacity to infect its host for decades without causing 
clinical disease. The reactivation only occurs in clinical situations where the immunity of 
the host is compromised [9]. The granuloma is the structure developed by the host in 
order to contain the infection and eliminate the disease, being produced after immune 
signal events. Thus, the infected AMs release cytokines to recruit different populations of 
cells, including macrophages to the infected site. In addition, dendritic cells present 
antigens to T cells in the lymph nodes, in which a T-cell response can subsequently be 
developed. The MTb persist in a latent state within the granuloma, often for decades, 
surrounded the infected cells (i.e. macrophages) by T cells, B cells, DCs, neutrophils, 
natural killer (NK) cells and fibroblasts (Figure 5) [40] that with their death cause the 
formation of a necrotic zone in the center of the granuloma, which eventually 
disintegrates, releasing the bacteria into the lung, and hence into the environment [9],[41].  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of TB granulomas. Adapted from [42]. 
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The MTb are ingested by the macrophages, being phagocytized. The 
phagocytosis involves membrane invaginations, which leads to the phagosome formation. 
Inside the phagosome, a hostile environment is created to the MTb. In fact, the bacillus is 
exposed to an acidic pH, reactive oxygen and nitrogen species (ROS and RNS), 
hydrolytic enzymes, and cationic antimicrobial peptides (CAMPs). The final steps of the 
bacterial destruction and clearance require the fusion between the phagosome and the 
lysosome [43]. Nevertheless, MTb is shielded from the environment by a robust cell wall, 
protecting and allowing the adaptation of MTb to the intracellular environment of 
macrophages and their survival even under drastic conditions. MTb is a bacillus shielded 
by a unique waxy cell wall composed of abundant glycolipids, mycolic acids (MAs), cord 
factor (TDM), peptidoglycans, and other carbohydrate, lipid, and protein molecules [44]. 
The mycobacterial cell wall differs from that of most other bacteria and forms a diffusion 
barrier, which is 100 to 1000-fold less permeable to hydrophilic molecules than that of 
Escherichia coli [45-46]. The success of MTb as a pathogen can be attributed to its 
extraordinary stealth and capacity to adapt to environmental changes throughout the 
course of infection. These changes include: nutrient deprivation, hypoxia, various 
exogenous stress conditions and, in the case of the pathogenic species, the 
intraphagosomal environment. Moreover, due to the highly hydrophobic waxy cell wall, 
bacilli are resistant to the digestion by liposomal enzymes and also resistant to the killing 
effects of macrophages [47]. Knowledge of the physiology of the MTb during this later 
stage has been limited by the slow growth exhibited by the bacterium in the laboratory 
[48]. In addition, although the exact nature of the carbon sources used during the infection 
remains unknown, MTb has been shown to metabolize host-derived cholesterol (CHOL) 
and triacylglycerol from the host cell and store the products in the form of intracellular lipid 
droplets [43].  
In the human host, the MTb is able to persist in a dormant state, causing latent TB 
without clinical disease (Figure 6). The bacterium enters into a nonreplicating stage with 
low-to-absent metabolic activity. A stimulus, as for example anti-TB drug treatment or 
immunosuppression of the host, may lead to the bacilli recover and grow to high 
abundance causing reactivation of TB. Nevertheless, MTb in a dormant and in a 
replicative stage seem to coexist and their balance will determinate the latent or the active 
TB [43]. 
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Figure 6. Schematic representations of the major steps from infection to disease in TB. Adapted 
from [49]. 
 
Less than 10% of  the infected individuals develop active TB (Figure 6). In the 
active disease, the number of pathogen increases exponentially by killing host cells and, 
by spreading through lymphatic circulation to regional lymph nodes in the lungs (3 to 8 
weeks after infection). A recent report showed that mycobacteria generates cell-to-cell 
heterogeneity by an asymmetric division and growing mother cell gives rise to daughter 
cells that differ in elongation rate and size (Figure 7). The resulting subpopulations of cells 
demonstrate different susceptibility to the antibiotics [50]. Later on, dissemination of the 
bacilli from the infected lungs to distant highly irrigated organs (e.g. central nervous 
system, spongy bone, liver, kidneys and genitalia) takes place (3 months after infection). 
At this stage, acute TB meningitis or disseminated TB can sometimes result in death. 
Finally, extrapulmonary manifestations (e.g. lesion in bones and joints) can appear [33]. In 
contrast with the pulmonary TB, the extrapulmonary TB is generally non-infectious [22]. 
 
 
 
 
 
 
 
 
 
Figure 7. Scanning electron microscope image of MTb showing the asymmetrical cell division. 
Arrows represent the asymmetrical cell division. Adapted from [10]. 
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1.5. Clinical Manifestations 
 
 The incubation of the MTb in the lungs corresponds to the primary pulmonary TB. 
In this stage when the symptoms appear are generally limited to a mild fever [51]. 
Nevertheless, the majority of people remain asymptomatic.  In a later stage of reactivation 
of TB the symptoms include, fever, cough, weight loss, fatigue, night sweats. Other 
symptoms as chest pain, dyspnea and hemoptysis may also occur, being although much 
less frequent [51-52]. Clinically, pulmonary TB is characterized by widespread lung 
damage in the form of areas of pulmonary atelectasis, fibrosis and scarring [53] resulting 
in decreased pulmonary compliance and impaired gas exchange. A similar clinical 
manifestation is observed in disorders related with pulmonary surfactant (PS) dysfunction 
[44],[47]. In the case of the extrapulmonary TB, the symptoms are strongly dependent of 
the organ system affected. For instance, in the skeletal TB the symptoms are general 
absent and when appear are restricted to a localized pain over the affected site. In the 
tuberculous pericarditis the symptoms are unspecific, including dyspnea, cough, 
orthopnea, edema. When the lymphatic and hematogenous are affected (miliary TB), 
systemic symptoms as fever, weight loss and night sweats are common. Septic shock and 
acute respiratory distress syndrome may also occur [51].  
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1.6. Diagnosis 
 
 Currently, conventional methods to identify MTb include microscopy, culture, 
radiography and serologic studies (Table 1) [54].  
Table 1. Key Features of Tests for TB. Adapted from [51]. 
 
Test 
 
Advantages Disadvantages 
Smear microscopy 
 
Ease, speed, and cost-
effectiveness of the technique 
Quantitative estimate of the 
number of bacilli  
Usefulness in determining 
infectiousness and in 
monitoring treatment 
progress 
Low sensitivity  
No capacity to differentiate 
from nontuberculous 
mycobacteria 
 
Chest radiography 
 
Ready availability  
Capacity to differentiate latent 
infection from active TB 
Low sensitivity and specificity  
Not confirmatory 
Tuberculin skin test High specificity in non–BCG-
vaccinated populations  
Cost-effectiveness 
 
Training required for 
administration and 
interpretation  
Return visit required in 48-72 
h for test result 
 Possible booster effect  
Possible false-positive and 
false-negative results 
Nucleic acid amplification 
test 
High specificity 
 Higher sensitivity than smear 
microscopy  
Rapid (1-2 days) diagnosis 
Capacity to differentiate TB 
from other mycobacteria 
 
Low sensitivity with smear-
negative TB  
Contamination-prone  
Technical skill and expertise 
required 
 Results may remain positive 
in patients who have 
completed treatment 
 High cost 
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The diagnostic method developed by Robert Koch 131 years ago is still used 
nowadays for the identification of MTb. The former method allows the observation of 
bacteria in cultures and in host tissues and is based on the adittion of methylene blue and 
brown counterstaining of the host tissues with vesuvin [43]. The sputum smear 
microscopy (SSM) diagnosis is one of the most widely used diagnostic tests for the 
identification of MTb, being simple and fast, however with several limitations (i.e. low 
sensitivity and the absence of capacity to differentiate from nontuberculous mycobacteria). 
The Ziehl–Neelsen is a commonly used coloration technique to demonstrate the acid-fast 
bacilli [55]. Still, this method does not distinguish between TB and nontuberculous strains 
and the identification of isolates may take a long time (up to 6 to 8 weeks) [54]. In 2009, 
the WHO recommended the sensitive fluorescent light-emitting diode (LED) microscopy 
instead of traditional Ziehl–Neelsen associated with optical microscopy. However, only 2% 
of the worldwide laboratories have LED microscopes [7]. The chest radiography has 
limited utility as a diagnosis tool for pulmonary TB since it presents poor specificity and 
reader inconsistency [56-57]. On the other hand, the tuberculin skin test, described by 
Koch in 1890 was until 2001 the only method capable of diagnosing latent TB [40]. This 
method measure the immune response against soluble antigens of MTb as a delayed-
type hypersensitivity reaction at the site of injection [58]. 
Fast and highly sensitive diagnostic tests that allow to identify MFR strains are 
recognized by the WHO to be a crucial key to effectively fight TB [59]. In this context, 
several diagnostic tests were developed. Xpert® MTb/RIF and Genotype® mtBdRplus are 
recent molecular assays with high sensitivity and specificity, based on the amplification of 
the MTb genome as well in the detection of a resistance to the most commonly used anti-
TB drugs. Xpert® MTb/RIF assay is a rapid molecular method, within 2 hours, the 
diagnosis of TB and the simultaneous assessment of RIF resistance, using unprocessed 
sputum samples or specimens from extrapulmonary sites [57]. The Xpert® MTb/RIF assay 
was endorsed by the WHO since 2010, being currently adopted by several countries [7]. 
Genotype® mtBdRplus assay is a fast diagnostic method that can be used from MTb 
isolates or directly from pulmonary smear-positive clinical specimens. In addition, this 
method allows to identify resistance to the RIF and isoniazid, by detecting the most 
common mutations within the hot spot region of the rpoB gene and katG, respectively [60]. 
Many other novel diagnostic techniques with potential to revolutionize the TB diagnosis 
are now available. Their introduction in the market has been delayed, in part due to their 
expensive cost and exclusion of many drugs for the resistance patterns profile [61].  
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1.7. Vaccines 
 
The only vaccine that exists for TB (i.e. Bacille-Calmette-Guérin, BCG) was 
developed almost a century ago by Albert Calmette and Camille Guérin of the Pasteur 
Institute, being part of the expanded program of immunization supported by the WHO 
since 1974 [62]. BCG consists of an attenuated form of Mycobacterium bovis [22],[63]. 
This vaccine provides limited protection and only during childhood, failing to protect the 
adult against pulmonary TB. In addition, BCG confers protection for a limited period and 
no longer than 10 to 20 years. [43]. Currently, there are more than 12 novel vaccines in 
clinical trials [64] but replacing BCG will not be easy, since it is one of the most widely 
used vaccines, and despite its limitations, is cheap, safe and well established [4]. The new 
vaccines aim to replace BCG by improving the recombinant BCG or by introducing 
genetically attenuated MTb, in order to be safer, more immunogenic, inducer a longer 
protection time and induce of protection against resistant MTb strains [65-66]. Three 
recombinant BCG strain constructs were designed to replace the BCG vaccine and have 
entered clinical trials, namely rBCG30, rBCGΔUreC:Hly and Aeras 422. The first and the 
second, rBCG30 and rBCGΔUreC:Hly are novel vaccine candidates that have 
successfully completed Phase I clinical trials. The first one is a BCG strain overexpressing 
the immunodominant MTb antigen 85B and the second one has the strain deficient in 
urease (with the consequence of an acidic pH in vaccine-containing phagosomes) and 
expresses listeriolysin (which enables it to perforate the phagosomal membrane. The 
third, Aeras 422, which expresses the similar pore-forming bacterial molecule 
perfringolysin has been discontinued following adverse effects in Phase I trials [67]. The 
second group includes MVA85A, AdAg85A and AERAS-402. These potential vaccines 
correspond to viral vectors that express immunodominant MTb antigens for the initiation of 
strong lymphocyte responses. The first and the second are in phase I and the third is in 
phase II clinical trials. Others, as Hybrid-1 possesses fusion proteins of immunodominant 
antigens with the aim to induce strong immune responses [68]. Examples of protein–
adjuvant vaccines include M72 in phase I, Hybrid 1 and HyVac4 are currently ongoing 
Phase I clinical trials. Mycobacterium vaccae is an inactivated whole-cell strain of 
Mycobacterium vaccae and was initially developed as a therapeutic TB vaccine 
candidate, being now considered a prophylactic vaccine [69]. In addition, RUTI® is made 
of detoxified, fragmented MTb cells, encapsulated in liposomes and it is in Phase I [70]. 
The objective of the WHO is the licensing and commercialization of at least one 
new vaccine by 2020 [62]. The introduction of new vaccines in the market is predicted to 
result in cost savings, as well as a reduction in TB morbidity and TB-related mortality [71]. 
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Additionally, vaccine conceived to be used in subjects infected with MTb will be the future 
of the research related with vaccines for TB [69],[72].	  	  
. 
1.8. Treatment 
 
Until the mid 1900’s, the only known cure for TB was a regimen of rest, fresh air, 
sunshine, and a hearty diet [73-74]. The incredible success of MTb as a human pathogen 
may be in part explained by its ability to avert the early control by T-cells. In fact, this 
contributes to explain the reason why parenterally administered vaccines have no effect 
on the replication of MTb in the lungs for 2 weeks after infection [38]. The use of drugs 
that induce the autophagy (a vital homeostatic process triggered by starvation and other 
cellular stresses), such as dexamethasone, rapamycin or vitamin D might be used to 
destroy MTb [75]. However, prolonged or excessive autophagy may caused an increased 
cell death [76]. Other approaches, such as phage therapy, start to be exploited as an 
alternative to the conventional chemotherapy. In fact, the phage therapy was a research 
topic before the discovery of antibiotics, especially in Eastern Europe and the 
Former Soviet Union and is nowadays gathering the TB researchers attention because of 
their biological characteristics, which may constitute an advantage in treating MDR-TB 
[55]. In addition, immunotherapy has a potential role in TB therapy. Thus, 
immunosuppressive agents could be considered in order to reduce the strong 
antibacterial immune response in the host [77].  
Despite the above-mentioned, the current chemotherapy using antibiotics with 
activity for the MTb is the most widely form of TB treatment and will be discussed in the 
next section. 
	  
1.8.1. Anti-tuberculosis drugs 
	  
Clinical management of TB using antibiotics poses serious questions due to the 
reduction of the efficacy of chemotherapy. This may be attributed to the degradation of the 
drug before reaching the target, the low levels of cell permeability to drugs or primary drug 
resistance. Other reasons for the failure of chemotherapy may be the difficulty in 
achieving adequately high drug concentrations at the infection site, inadequate 
penetration into macrophages, and low stability levels in cells [34],[78]. The treatment of 
TB is also complicated because MTb are intracellular pathogens that reside inside 
macrophages, and show low metabolism. Therefore, the treatment is made for 6 months 
or longer with combinations of agents to minimize the emergence of antimicrobial 
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resistance [70],[79]. The necessity of an extended period of treatment is a direct result of 
the lifecycle of the bacilli, some of wish may enter into a “dormant” or “persistent” phase 
after the initial infections [80].  
These long treatment schedules are associated with severe toxic side effects, 
including hepatotoxicity, and result in poor compliance, one of the main reasons for the 
emergence of MDR strains [81-82].  
The most effective pharmacotherapy is comprised of a multi-drug combination of 
isoniazid, pyrazinamide and RIF. During the initial intensive stage (2 months), these three 
agents are administered together with ethambutol. The second phase (4 months) 
comprises exclusively RIF and isoniazid. These four drugs, together with streptomycin, 
make up the so called first line therapy [8],[83]. Additionally, streptomycin was the first 
anti-TB drug used in therapy, being used since 1944 [84]. The therapeutic regimen 
recommended by WHO is highly effective and presents cure rates of around 90% in HIV-
negative patients. In the cases of MDR-TB, the treatment currently recommended by the 
WHO comprises 20 months of treatment with second-line drugs for most patients, and are 
associated with multiple (and sometimes serious) side-effects and lower cure rates [7]. 
Isoniazid, a pro-drug, when activated has as main targets the NADH-specific 
enoyl-acyl carrier protein reductase and β-ketoacyl acyl carrier protein synthase, involved 
in MAs synthesis. Depletion of MAs results in bacterial killing [85]. RIF, a lipophilic 
ryfamicin derivative, binds to the β-subunit of RNA polymerase and inhibits RNA 
transcription and consequently, protein synthesis in MTb. Pyrazinamide, a pro-drug, is 
highly effective against semidormant bacilli in acidic environment (like macrophages). It is 
activated by pyrazinamidase to pyrazinoic acid, which by lowering intracellular pH, 
inactivates a vital fatty acid synthase, targets enzymes participating in the synthesis and 
polymerization of the cell wall arabinan, and interacts with three homologous, membrane 
associated arabinosyltransferases. It also affects proteins encoded by isoniazidinducible 
genes and acyl carrier proteins and other proteins regulating their expression. 
Streptomycin binds to a ribosomal protein and 16S rRNA causing misreading of mRNA 
and faulty protein synthesis. This drug may be used as a first-line or second-line drug for 
treating patients with failing therapy or MDR-TB [86]. The second-line drugs are generally 
more toxic, more expensive and less active than first-line agents and include drugs like 
RFB, ethionamide, amikacin, kanamycin A and levofloxacin [33]. Aminoglycosides, 
kanamycin and amikacin also inhibit protein synthesis (peptide chain elongation). 
Fluoroquinolones such as levofloxacin inhibit DNA replication by DNA gyrase inactivation 
and are important second-line drugs for treating MDR-TB. Ethionamide, a structural 
analog of isoniazid, is used as a second-line drug for MDR-TB and shares the target with 
isoniazid. Similar to isoniazid, ethionamide is also a pro-drug, however, it is activated by a 
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monooxygenase [86]. RFB (like RIF binds to β-subunit of RNA polymerase and inhibits 
RNA transcription and consequently, protein synthesis) has been demonstrated to have 
activity against M. avium complex in both in vitro and in vivo models [13]. RFB is mostly 
used in HIV co-infected patients because it has fewer drug interactions with antiretroviral 
agents than RIF [46]. 
Currently, there are ten TB drug candidates in clinical trials. The aim is to find 
compounds that allow the improvement of the compliance to the therapy. Thus, finding 
effective drugs against resistant strains, with fewer side effects and that allow the 
reduction of the duration of the treatment [59]. In this context, TMC207, a recently 
discovered inhibitor of the F0/F1 ATP (adenosine triphosphate) synthase, is active against 
non-replicating MTb and is in Phase II clinical trials [73]. Others as PA824, and 
OPC67683 in Phase II clinical trials, and SQ109 and LL-3858 in Phase I trials. However, 
even for these drugs, with a new mechanism of action, the resistance develops in vitro at 
rates similar or even faster than the existing drugs [73]. On the other side, TMC207 
(bedaquiline) already has FDA approval for MDR-TB under the FDA’s accelerated 
approval for orphan drugs, being this drug associated with an increased mortality in the 
treated group [87-88]. Rifapentine (a ryfamicin with longer half-life than rifampicin) as part 
of a 4-month regimen for the treatment of drug-susceptible TB is evaluated, being this 
compound in phase III clinical trials. Others are also in advanced clinical development 
(phase III trial), such as delamanid (OPC-67683), gatifloxacin and moxifloxacin [7],[89]. 
Although the development of new anti-TB drugs is an obvious approach to fight 
TB, mechanisms to improve the efficacy of the existing drugs can represent a faster 
strategy [90]. In this regard, improvement of the therapeutic index of existing anti-TB 
drugs should be considered, aiming at the maximization of the drug concentration at 
infected sites, reduction of toxic effects and reduction of the treatment duration. This may 
be obtained for instance by the encapsulation of the drugs in nanoparticles and in another 
hand by the improvement of the pharmacokinetics properties of the existing antibiotics 
[28]. 
 
1.8.1.1.  Rifabutin and Analogs 
	  
RFB, (Figure 8) discovered in 1980, [91] has a broad spectrum of antimicrobial 
activity, including activity against mycobacteria, a variety of Gram-positive and to a less 
extent Gram-negative bacteria, and also protozoans such as Toxoplasma gondii. RFB is 
commonly used to treat Mycobacterium avium and MTb. It is also useful in the treatment 
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of Helycobacter pylori infections and specially indicated in the case of eradication failures 
using other antibiotics [92].  
RFB is a ryfamicin derivate and its mechanism of action constists of a specific 
inhibition of DNA-dependent RNA synthesis in prokaryotes. The binding constants for 
prokaryotic RNA polymerases are 10.000 fold stronger than eukaryotic RNA polymerase. 
In addition, a single point mutation in the bacterial RNA polymerase enzyme accounts for 
the majority of the resistances for RFB. The DNA-dependent RNA polymerase is a 
complex enzyme with an α2, β, β’ and σ-subunit structure. The binding site for RFB on the 
RNA polymerase occurs at the β structure, which is encoded by the rpoB gene [93-94]. 
RFB is a inducer of the CYP3A, being also metabolized by these enzymes [95]. 
Therefore, it is used as an alternative to RIF in subjects coinfected with HIV and MTb [96]. 
RFB is generally well-tolerated but there are some problematic side effects, which include 
uveitis, rash, nausea, vomiting, neutropenia, anemia, discoloration of the skin and body 
fluids (tears, saliva, urine and perspiration), and, rarely, clinically important impairment of 
the liver function [92]. 
RFB is listed in the WHO essential medicines. Most of the studies show that its 
efficacy is higher or even higher than similar drugs as RIF [97].  However, its high cost 
when compared with other similar drugs (e.g. RIF) makes its choice almost inaccessible in 
the worldwide TB control programs [98]. 
RFB is a highly lipid-soluble compound, [97] showing an apparent terminal half-life 
of 45 h (range 16 to 69 h) [96]. After a single oral dose (usually 300 mg) it shows a great 
absorption and distribution. The maximum plasma concentration achieved is 0.37–0.9 
mg/L [92]. In addition, RFB shows higher penetration in the lungs and infected cells (e.g. 
macrophages) [97]. The extent of binding to plasma proteins varies between 71% and 
94%, being RFB extensively metabolised, specially in the liver [92]. In addition, the log P 
predicted for RFB using MarvinView 5.11.5 from Chemaxon® is 4.53. The RFB molecule 
contains some groups that can undergo protonation (piperidine nitrogen, pKa 9.5 and 
imidazole nitrogen, pKa 3.5) and deprotonation (naphthol oxygen, pKa 6.5). At the 
physiological pH, while zwitterionic species predominate (83.4%), cations make up 16.6% 
(predicted using MarvinView 5.11.5 from Chemaxon®). 
Regarding the concerns about TB, RFB was chosen as the lead compound for 
new analogs showing to be promising molecules against TB. Herein, N’-acetyl-rifabutin 
(RFB2) and N’-butanoyl-rifabutin (RFB3) (Figure 8) were obtained from RFB, using a 
selective acylation of the secondary amine [80]. In comparison to RFB, RFB2 has an extra 
acetyl group (COCH3) and has shown better in vitro and in vivo therapeutic index, thereby 
being a promising drug for clinical application in TB treatment. RFB3 has a bulkier group 
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in its constitution, namely butanoyl (COC3H7), added with the major goal of improving the 
pharmacokinetics properties as an anti-TB drug candidate [80]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Chemical structure of rifabutin (RFB), N’-acetyl-rifabutin (RFB2) and N’-butanoyl-rifabutin 
(RFB3). 
 
 
Additionally, the predicted log P is 5.53 for RFB2 and 5.68 for RFB3 using 
MarvinView 5.11.5 from Chemaxon®. Therefore, the substitution of a hydrogen atom in the 
imidazole ring by an acetyl or a butanoyl group leads to an increment of the molecules 
hydrophobicity. This substitution leads to the reduction of the positively charged 
molecules. 
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2. Biological Cell Membranes 
	  
“Cellular organization, far from an afterthought, must have been from the 
beginning part and parcel of the origin of life. . . Therefore a believable biopoetic scheme 
is one that creates mounting levels of biological order naturally, by providing the means to 
convert the flux of energy into the organization of matter. This seems to me inconceivable 
without compartments.” [99] 
 
Franklin Harold, 1986 
 
Cells are the basic unit of all living organisms, being the membrane lipid bilayer the 
structure that delimits the surrounding environment that serve as the margin between life 
and death [100-101]. In fact, all cells have a cell membrane composed of amphiphilic 
compounds, which results in a closed interior compartment separated from the outside 
world. The cells are also formed by several internal compartments (i.e. organelles), which 
are also separated by membranes [102-103]. The cell membranes control the exchange 
of matter and energy with the extracellular environment or with the cytosol in the case of 
the internal compartments [102],[104]. 
Biological membranes composition varies extraordinarily depending of the cell 
(eukaryotic or prokaryotic) and even within the cell, being their complex organization also 
dynamic in order to mediate and modulate conformational changes, signaling, trafficking, 
and recognition [105]. 
Generally, cell membranes composition consists in a mixture of phospholipids, 
proteins and other macromolecules, constituting one biological example of a complex and 
multifunctional self-assembling nanosystem (Figure 9) [102]. 
 
 
 
 
 
 
 
  
Figure 9. Schematic representation of the basic structure of the cellular membrane. Adapted from 
[106].  
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2.1. Membrane Functions 
 
The most basic and important function of biological membranes is to define a 
boundary, whether between or within cells and the internal compartments (Figure 10). In 
fact, the membrane provides an internal compartment that allows spatial control of 
different functions, being its barrier function considered fundamental for the appearance of 
life on the early Earth [107].  
Many cellular processes depend upon the ability of the cell membrane to isolate 
different areas, while enabling communication and tightly regulated transport within and 
across membranes [107-108].  
 Other important functions of the cell membranes include the creation of chemical 
and electrical gradients, the regulation of the transport of solutes in the inner and outer 
compartments of the cells, the control of the activity of membrane bound enzymes 
accommodating them to perform their metabolic functions in a coordinated way, the 
providing of substrates for metabolism (e.g. arachidonic acid in the prostaglandin 
synthesis) and the promotion of signal transduction and protein trafficking [109]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Schematic representation of the membrane functions. 
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2.2. Membrane Structure 
 
The lipid bilayer was recognized by Gorter and Grendel in 1925 as the basis for 
cell membrane architecture [110-111]. Indeed, the cell is to the living organism as the lipid 
bilayer it is to the biological membranes. Proteins were added to the comprehensive 
picture of membranes, first in 1935 by Danielli and Dawson, and later in 1966 by 
Robertson’s unit membrane model [110]. However, detailed study of the structure of cell 
membranes began merely four decades ago with the fluid mosaic model proposed by 
Singer and Nicholson in 1972 [111]. This model hypothesized the membrane as a fluid 
lipid bilayer with proteins that diffuse freely within the plane of the cell membrane [112]. 
After that it was discovered the existence of large membrane domains (e.g., basal, lateral 
and apical membrane regions of glandular, endothelial and epithelial cells) and lateral 
microdomain structures (e.g., lipid rafts, caveolae, and coated pits) [111]. Lipids rafts are 
an example of a domain where lipids of a specific chemistry are associated with each 
other in order to form key platforms for membrane protein sorting and construction of 
signaling complexes [113]. In addition, the knowledge that the lipids via alterations in the 
membrane pressure profile may regulate protein and channel function, states the 
importance of the lipid bilayer in the membranes. For instance, certain drugs (e.g. 
anesthetics) exert part of their action on membrane proteins and receptors via changes in 
the pressure profile [110]. Currently, membranes are viewed as a mosaic of different 
compartments or domains maintained by an active cytoskeleton network (Figure 11) [113-
114]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Schematic representation of the modern concept of celular membrane structure. 
Adapted from [114].  
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2.3. Membrane Composition 
 
Biological membranes present a substantial variability in their composition and 
physical properties, depending of the cell (prokaryotic or eukaryotic) and even within the 
cells (e.g. according to the organelle). Nevertheless, all biological membranes contain lipid 
bilayers as its basic structural unit [115]. Generally, membranes are formed by lipids, 
protein and other macromolecules (e.g. carbohydrates) [102]. In addition, cell membranes 
can be interpreted as a two-phase system consisting of the lipid raft phase, enriched in 
CHOL, and proteins and saturated lipids, dispersed in a matrix phase [116]. 
The lipids present in the membranes can be divided into three groups based on 
their chemical structure: glycerophospholipids (or phospholipids), sphingolipids and 
sterols (Figure 12) [117].  
 
 
 
 
Figure 12. Composition of membrane lipids and their chemical structures. Adapted from [117]. 
 
Glycerophospholipids are amphiphilic molecules composed by a hydrophilic head 
group formed by an alcoholic group, a phosphate and a glycerol molecule. The glycerol 
molecule connectes the polar head group with two hydrophobic alkyl chains (Figure 13).  
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Figure 13. Schematic structure of a glycerophospholipid [118]. 
 
The self-assembly of the glycerophospholipids into two-dimensional bilayer sheets, yields 
to the cell membrane a thickness of approximately 5 nm. The hydrocarbon tails of the 
glycerophospholipids are hydrophobic, densely packed and therefore shielded from the 
aqueous moiety [102]. Glycerophospholipids are further divided into different groups 
based on their hydrophilic head groups. The most common alcohol moieties found in the 
glycerophospholipids of the membranes are the aminoacid serine, ethanolamine, choline, 
glycerol, and the inositol (Figure 14) [118].  
 
 
Figure 14. Schematic structure of the most common alcohol groups of the glycerophospholipids. 
Adapted from [118]. 
 
Examples of glycerophospholipids commonly found in biological membranes include, 
among others,  phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
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phosphatidylserine (PSer), phosphatidylinositol (PI), cardiolipin (CL), and 
phosphatidylglycerol (PG) (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Schematic structure of the most common glycerophospholipids found in  membranes. 
 
Regarding the negative charge of the phosphate group, lipids with an alchool group 
without charge or with zwitterionic charge are negatively charged phospholipids (e.g. PI, 
CL, PG, PSer). Others are zwitterionic phospholipids (e.g. PC, PE) because of the 
positively charged alchool group. 
The hydrocarbon chains present in the phospholipids can differ in their length or in 
the number of unsaturated bonds. The most common in natural membranes are the 
saturated fatty acids, such as the palmitic (C16), stearic (C18), and myristic (C14). From 
the unsaturated fatty acids, the oleic (C18:1), a stearic acid with one double bond in the 
middle of the chain, is the most frequent in the membranes. The majority of the natural 
lipids contain one or more double bonds in cis conformation (e.g. higher animals, plants), 
while a trans conformation is found in the Monera kingdom. Generally the number of 
double bonds increases with the length of the hydrocarbon chain, being more frequent to 
find an even number of carbons in the hydrophobic chains of each phospholipid, than an 
odd number, which are found in rare cases [119]. 
Sphingolipids are phospholipids that have a sphingosine, an amino alcohol as a 
backbone, which contains a long, unsaturated hydrocarbon chain, conferring greater 
hydrophobicity to the core of the lipid bilayer [120]. The major sphingolipid in mammalian 
cells is sphingomyelin (SM) [100]. In sphingomyelin, the amino group of the sphingosine is 
linked to a fatty acid by an amide bond, being the primary hydroxyl group of sphingosine 
esterified with a phosphoryl choline (Figure 12) [118]. CHOL (Figure 12) is the most 
representative sterol of the animal eukaryotic membranes. It is a steroid built from a 
PC PE PSer PI CL PG 
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hydrophilic hydroxyl group, that interacts with the phospholipids’ hydrophilic head groups 
and a bulky steroid group, which interacts with the hydrophobic acyl chains of lipids 
[111],[121]. CHOL has a “schizophrenic” behaviour in the membranes, decreasing the 
membrane fluidity in fluid phases and increasing the membrane fluidity in gel phases 
[122].  
The lipid rafts are aggregates of phospholipids, CHOL and glycosphingolipids 
associated with key biological processes, such as endocytosis, signaling, protein 
transport, apoptosis, and cytoskeleton organization (Figure 16) [100],[123]. 
The proteins present in the membranes may be only bounded to the surface or 
have one region buried within the membrane (Figure 16). Therefore, membrane proteins 
can be classified into two broad classes, integral (intrinsic) and peripheral (extrinsic), 
based on the nature of the membrane-protein interactions. The majority of the biological 
membranes contain both types of membrane proteins. Most integral proteins contain 
residues with hydrophobic side chains that interact with the hydrocarbon tails of the 
phospholipids of the membranes. On the other hand, the extrinsic proteins do not interact 
with the hydrophobic core of the phospholipid bilayer, establishing interactions with the 
integral membrane proteins or with the phospholipid polar head groups of the 
membranes. For instance, one of the most important proteins of the eukaryotic plasma 
membrane includes the cytoskeletal protein spectrin, which lines the intracellular side of 
the membrane [106]. The plasma membrane contains proteins that act as sensors (e.g. 
receptors) of external signals, allowing the cell to change its behaviour in response to 
external signs [106],[124]. 
Glycoconjugates are carbohydrate molecules bounded to a lipid or protein (Figure 
16). These molecules may be classified into four typical family groups: proteoglycans, 
glycoproteins, glycolipids and glycosylphosphatidylinositol (GPI)-anchored proteins. 
Glycoconjugates play essential roles in many physiological processes of the membranes, 
such as cell growth and development, and cell-to-cell interactions and recognition. In 
adittion, glycosphingolipids and GPI-anchored proteins participate in the production of 
rafts in the membranes [125-126].  
In specialized membranes, ionic channels are also present, being used to 
generate the ion gradients across the membranes and synthese of energy (e.g. ATP), to 
drive the transmembrane movement of selected solutes, or, in nerve and muscle cells, to 
produce and transmit electrical signals [106],[124]. 
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Figure 16. Simplified model of lipid-raft structure in biological membranes. Adapted from [127]. 
2.3.1. Molecular Composition in Eukaryotic Cell Membranes 
The eukaryotic cells exhibit an impressive number of well-defined internal 
membranes associated with the nucleus and the organelles. There is a remarkable 
difference concerning the membrane composition between the plasma membranes and 
that of the various organelles (Figure 17). For instance CHOL, a universal molecule in the 
membranes of all animals (sitosterol in plants and ergosterol in fungi) in amounts between 
20-50% (total lipids) is much less representative in the membranes that outline the 
organelles, as the mitochondria (less than 5%), Golgi (approximately 8%) and 
endoplasmic reticulum (roughly 10 %) [119],[128-129]. CHOL is responsible for the 
regulate of the degree of membrane fluidity–rigidity. In addition, as above-mentioned, 
CHOL is an important component of the so-called “lipid rafts” [130]. Lipid rafts are also 
formed by sphingolipids and proteins and are phase-separated micro-domains in 
biomembranes, forming the rigid and relatively ordered state, generally defined as the 
liquid ordered (Lo) phase [131-132].  
glycerophospholipids cholesterol 
sphingolipids 
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Figure 17. Lipid composition of different membranes varies throughout the eukaryotic cell. The lipid 
composition (shown in graphs) are expressed as a percentage of the total phospholipids in 
mammals (blue) and yeast (light blue). Adapted from [100]. 
There is an asymmetry in the lipid composition of the two monolayers of the bilayer 
of the plasma membrane [133]. In the outer monolayer, the more prevalent lipids are the 
PC, SM, CHOL and glycolipids. On the other side, the PSer, PI and PE are the most 
representative lipids of the inner monolayer. The membranes of the eukaryotic cells are 
predominantly composed of zwitterionic lipids. The standard membrane lipid is the 
zwitterionic PC, comprising 50% of the cellular lipids [120]. The amount of the negatively 
charged lipids present in the eukaryotic membranes is approximately 10%, being the 
positively charged lipids absent [106],[119],[134]. 
The phospholipids and the CHOL of the plasma membranes are mainly 
synthesized on the cytosolic surface of the ER, while PE is also generated by PSer 
decarboxylation in mitochondria [120]. After the phospholipids production, the protein 
“flippase” (Figure 18) facilitates the energetically unfavorable movement of a 
phospholipid’s polar head group through the hydrophobic membrane interior [135]. The 
mentioned ER flippase does not require metabolic energy, mediating a rapid transverse 
movement of most of the phospholipids and promoting a symmetrical transbilayer lipid 
distribution. The asymmetry of the plasma membrane is maintained due to the energy-
dependent flippase, the aminophospholipid translocase (APLT) that uses ATP hydrolysis 
to catalyze a fast, inward translocation of PSer and PE to the cytoplasmic leaflet. 
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Additionally, the loss of lipid asymmetry as well the exposition of Pser at the cytoplasmic 
leaflet are signals that trigger cell apoptosis, promoting the engulfment of apoptotic cells 
by the immune systems cells as the macrophages [135]. 
 
 
 
 
 
 
 
 
Figure 18. Flippase mechanism. Transmembranar flippase (orange) provides a central hydrophilic 
path for the transiting headgroup while leaving the hydrophobic chains of the lipid (gray) in the 
bilayer. Adapted from [136]. 
2.3.2. Molecular Composition in Prokaryotic Cell Membranes  
Normally, the prokaryotic cells only have a plasma membrane and some structured 
internal membrane systems. The membranes of prokaryotes possesses great differences 
in comparance to the eukaryotic cell membranes and for instance, the sterols (including 
CHOL) are universally absent [119],[128] (Figure 19).  
 
 
Figure 19. Schematic representation of the main differences between eukaryotic and prokaryotic 
cell membranes.  
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Remarkably, the prokaryotic show a greater variety in their membrane composition in 
comparison to the eukaryotic, being the membrane’s composition an important parameter 
for the species identification (Figure 19) [119]. 
The glycerophospholipids are the primary building blocks of the bacterial 
membranes, being the lipids PG, CL, PE and PI the most representative in prokaryotic cell 
membranes [137],[138]. The lipid synthesis in the bacteria occurs in the cytoplasmic 
membrane by enzymes that are predominantly integral membrane proteins with the 
catalytic domain in the cytoplasm [139-140]. 
The prokaryotes have the ability to modify the biochemical composition and 
properties of their membranes in order to survive to the hostilities of the environment. One 
of the mechanism of resistance to the cationic antibiotics is the addition of positively 
charged amino acids to PG, lowering the net negative charge of their cellular envelope, 
thereby decreasing the affinity of several antibacterial agents [137].  
The domains also exist in the bacterial membranes, being the knowledge about its 
function and composition very scarce. Contrastingly to the mammalian membranes, lipids 
as the CHOL and sphingomyelin are not included in the domains composition. On the 
other hand, lipids (e.g. CL and PE) and proteins seem to compose the bacterial lipid 
domains [141].  
There are major structural and chemical composition differences between Gram-
positive and Gram-negative bacteria (Figure 20 and 21). Generally, Gram-negative 
bacteria contain both anionic and zwitterionic phospholipids, while many Gram-positive 
bacteria contain predominantly anionic lipids [142]. Thus, Gram-negative bacteria have a 
highly permeable outer membrane that contains lipopolysaccharides (LPS) on its outer 
leaflet, with the inner leaflet composed mainly of zwitterionic phospholipids as the PE. 
Gram-positive bacteria have lipoteichoic acid (LTA) adhered to the cell surface 
membrane, which contain predominantly PG and CL lipids [141]. Both possess in its 
constitution a peptidoglycan layer outside of the cell membrane, being thicker in the case 
of the Gram-positive bacteria [141]. The mycobacterial cell wall is formed by a thick waxy 
mixture of lipids and polysaccharides, being characterized by the presence of a high 
content of MAs (Figure 20 and 21). MAs are α-alkyl-β-hydroxyl high molecular weight fatty 
acids. Each molecule consists of a hydrophobic long saturated 2-alkyl branch and a 
hydrophilic head group (containing the groups COOH and OH) [143], occuring in the cell 
wall of MTb as variable mixtures of different classes (α-MA, methoxy-MA and keto-MA) 
[144-145]. In addition, the major MAs-containing molecule, the glycolipid trehalose 6,6′-
dimycolate (TDM, cord factor) has an important role in the physiopathology of the 
mycobacteria [146]. The mycobacterial plasma membrane appears to be a typical 
bacterial membrane and resembles a Gram-positive wall. However, some controversy 
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may be found in the literature related with their classification with the Gram stain 
[142],[148],[150]. If a Gram stain is performed on Mycobacterium species, it stains very 
weakly Gram-positive or not at all (cells referred to as "ghosts"), being the Ziehl-Neelsen 
stain a more accurate method for the identification of the Mycobacterium species  [147]. 
For the former reason, the Mycobacterium species are commonly classified as acid-
fast Gram-positive bacteria due to their lack of an outer cell membrane [142],[148-149]. 
Notwithstanding, the phylogenetic classification of Mycobacterium species is controversial 
because their cell wall has characteristics of both Gram-positive and Gram-negative 
bacteria [150]. In addition, the most common phospholipids in the mycobacterial plasma 
bilayer include PI, CL, PG, PSer and PE [151-153]. The PI, a precursor for more complex 
glycolipids, such as the PI mannosides (PIMs) and lipoarabinomannan (LAM) seems to be 
a phospholipid with important roles in the structure and physiology of these bacteria as 
well as during host infection [152-153]. 
 
 
Figure 21. Schematic representation of the differences between Gram-positive, Gram-
negative and Mycobacterial cell membranes. 
 
 
 
 
 
 
 
 
Figure 20. Schematic representation of bacterial cell walls (A - Gram-positive bacteria; B – Gram-
negative bacteria; C - Mycobacteria). Adapted from [154] 
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Figure 21. Schematic representation of the differences between Gram-postive, Gram-negative and 
Mycobacteria cell membranes. Adapted from [154]. 
2.4. Pulmonary Surfactant Membrane 
The first evidences of the existence of a surface material, that eases the lungs´ 
expansion and stabilizes the terminal airways, emerged in 1920 with the pioneer work of 
the Danish physician Kurt von Neergard [155]. After that, the PS was remarkably related 
within neonatal respiratory distress syndrome, allowing the utilization of natural or 
synthetic surfactant in the clinical practice since 1980 [156-157]. Its use is further 
indicated in meconium aspiration syndrome, persistent pulmonary hypertension, 
pulmonary haemorrhage, pneumonia and delivery of drugs directly to the lung, including 
antibiotics, anti-inflammatory agents and bronchodilators [26],[158].  
 The PS (Figure 22) is a thin and fluid layer that decreases the surface tension 
between the gaseous-aqueous interface in the lungs [159].  
 
 
 
 
 
 
 
 
 
Figure 22. Schematic representation of the PS in an alveolus of the lung. Adapted from [160]. 
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The PS surfactant main role is the reduction of the alveoli surface tension, allowing the 
reduction of the respiratory work and the prevention of alveoli collapse. Besides this 
crucial function, it contributes to the small airway permeability and improves the 
mucocilliary depuration [161-162]. The PS is produced by the ER of the type II alveolar 
epithelial cells, being stored in lamellar bodies (LBs). Once secreted in response to 
extracellular signals, the extracellular pool of the phospholipids within LBs transforms into 
a surfactant film that lines the alveolar surface [163-164]. Additionally, the phospholipid 
fraction obtained from bronchoalveolar lavage contains a number of different 
morphological and biochemical forms of surfactant including multilamellar and unilamellar 
vesicles (Figure 23) [163].  
 
Figure 23. Schematic representation of the PS polymorphism. Adapted from [165]. 
 
The PS is composed of: 80% phospholipids, 8% neutral lipids, and 12% proteins, 
including proteins from plasma and lung tissue, as well as, four surfactant-related proteins 
(Figure 24) [164],[166]. DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), the main 
component of the lung surfactant system is the primary responsible for its unique property 
of reducing the surface tension to near zero-values. Due to its main transition temperature 
of approximately 41 ºC, at the body temperature the surfactant exists in the gel phase. 
This, although adequate to reach a low superficial tension, results in a low capacity for 
adsorption at the interface. Thus, surfactant lipids such as unsaturated 
phosphatidylcholines, CHOL and other, help DPPC in this task [35],[167].  
Four surfactant proteins have been identified so far (SP-A, SP-B, SP-C, and SP-
D), and are classified by their hydrophilicity (SP-A, SP-D) versus hydrophobicity (SP-B, 
SP-C). These proteins play a key role in the performance of the surfactant surface, as well 
as in the immunological defense and particle depuration. (89) While the main function of 
Theoretical	  Background	  
	  38	  
SP-A and SP-D is to participate in innate pulmonary immune defenses, SP-B and SP-C 
interact extensively with surfactant phospholipids and increase their ability to efficiently 
lower surface tension. PS contains a small percentage of neutral lipids that are generally 
comprised of CHOL, CHOL esters, diglycerides, triglycerides, and free fatty acids whose 
functions have not been fully characterized but seem to have a part in supporting DPPC 
adsorption at the interface [168].  
 
Figure 24. Composition of human PS. Adapted from [169]. 
 
2.5. Lamellar Phase Transition 
  The “hydrophobic effect” of the phospholipids is due to their amphiphilic properties 
and happens in order to minimize the contact between lipid hydrocarbon tails and the 
aqueous environment, which results in self-assembled “polymorphs” in the hydrated state. 
At zero to low hydrations and/or temperatures most of the lipids form crystalline phases 
(Lc), generally of the lamellar type. In the former phase, phospholipids possess short and 
long ranges similar to true crystals.The lamellar phase is characterized by one-
dimensional stack of lipid bilayers separated by water layers. Each bilayer is formed by 
two monolayers stacked back-to-back, thus protecting the hydrocarbon chains from the 
contact with the water [131]. Molecules with cylindrical shapes would predominantly yield 
lamellar bilayers (Figure 25A),  whereas molecules with conical shape would stabilize 
phases with curvature, such as hexagonal and cubic phases (Figure 25B) [110].  
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Figure 25. Schematic drawing of lipid-water phases (A – Lamellar phases; B – Isotropic phases 
(cubic and hexagonal)). Adapted from [170]. 
 
Since the early 1980s, it was determined that the geometric shape of the 
phospholipids determines the “preferred phase” exhibited in aqueous solution (Figure 26) 
[171].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Schematic representation of the phospholipid packing in solutions (A – Lamellar phases 
and tend to form bilayer structures; B- Cone shaped phospholipids and tend to form micelles or 
inverted truncated cones; C- Cone shaped phospholipids and tend to form inverted micelles or 
hexagonal phases. Adapted from [171]. 
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Therefore, the geometry of the phospholipids is cylindric, when the cross-sectional areas 
of the head groups and acyl chains are the same. When the phospholipid head group 
area is larger than the acyl chains, the lipid assumes the shape of a cone or a wedge and 
tends to form normal hexagonal (HI) phases. On the other hand, if the phospholipid head 
group is small and the acyl chains are larger, the lipid seems an inverted cone, tending to 
form inverted hexagonal (HII) phases or inverted micelles [171]. However, the morphology 
of the phospholipids will be dependent of several other factors such as the degree of 
hydration of the phospholipid head groups, the pressure and the temperature [172]. Some 
of the phospholipids, as the PCs and PGs, generally form bilayer structures (Figure 25A). 
Moreover, PE is a class of lipids abundantly found in biological membranes and prone to 
form an inverted hexagonal phase (HII) (Figure 22B) [173]. 
In the non-lamellar phases the more common arrangements include the hexagonal 
and cubic phases. The HI and HII lipid phases are phases in which the lipids form tubular 
structures. In the HI phase, the center of the cylinder is made up of the hydrophobic tails, 
while in the HII phase the hydrophobic tails face outwards and the core of the tube is 
comprised of the polar head groups (Figure 25B). The cubic phases are lipid aggregates 
that form a three-dimensional lattice (Figure 25B) [171]. 
  In the lamellar phases, lipids could be present in three different phases: the gel 
phases (denoted by Lβ, Lβ’ or Pβ’), the liquid-ordered phase (Lo), and the liquid crystalline 
or fluid phase (Lα) (Figure 27). In the Lβ the hydrocarbon chains are packed into 2D 
hexagonal lattices in their all-trans conformation. In this phase, the chains are ordered 
parallel to the normal bilayer. Additionally, when the polar head group area-packing 
requirement exceeds twice that of the chains (for diacyl lipids), the tilted gel (Lβ’) is formed. 
The lamella of the gel phase may undertake periodic modulation, resulting in a rippled 
phase (Pβ’), which exists in some phospholipids (e.g. PC, PG) and is formed just below 
the fluid lamellar phase (Lα). The former phase happens upon melting of the crystalline 
and gel phases where the polar head groups are totally disordered and the the chains are 
fluid, closely resembling the cell membranes [113],[174]. In addition, the Lα is a perfect 
example of a liquid-crystalline phase. The sub- pre-, and main phase transition 
temperatures can thus be ascribed respectively to the LC→Lβ′, Lβ′→Pβ′, and Pβ′→Lα phase 
transitions [172]. The Lo phase is an intermediate phase between the gel and the fluid 
phases, not only being characterized by a highly lateral mobility of the lipids but also by an 
ordered structure with extended fatty acids [131],[175].  
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Figure 27. Scheme illustrating the different physical states adopted by a lipid bilayer in aqueous 
medium. Adapted from [176]. 
2.6. Membrane Model Systems 
In the last years, the knowledge about cell membranes has been tremendous and 
in part was brought by the development of membrane models systems [177-178]. In fact, 
the cell membrane is an impressive complex system where every part is connected with 
each other [179]. Thus, the design of a cell membrane model implies a simplification of 
the biological membranes. One of the major drawbacks pointed to the actual membrane 
models systems of the cell plasma membrane is the lack of asymmetry and the absence 
of proteins in their constitution [180]. However, these issues may be surpassed and for 
instance the insertion of proteins in the lipid bilayer starts to be common in the design of 
membrane model systems [181]. Notwithstanding, in the biophysical studies of drug-
membrane interactions, of more importance that the imitation of nature is the development 
of suitable membrane model systems that allow to understand the interactions of the drug 
at the molecular level. In the biophysical investigations, the use of membrane model 
systems permit to understand the diffusion of the drugs through the membrane lipids and 
their distribution, and therefore the prediction of the potential toxicity of the drugs [111]. In 
recent years, membrane models have also been studied to understand their mechanisms 
of interaction with peptides and nanocarriers, which can be useful in the design and 
development of efficient drug delivery systems [182]. The main advantage in the utilization 
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of the membrane models is the possibility to perform the experimentations under 
conditions that the cells may not be able to withstand and remain viable. In addition, the 
usage of membrane models allow to study the drug-membrane lipid bilayer interactions 
with the head groups of lipids, with hydrophobic alkyl chains, and with both head groups 
and hydrophobic acyl chains [178]. Independently of the target position (intracellular or 
located within the membrane), the drug molecules must interact with the membranes 
before reaching their targets and elicit a pharmacological action; therefore, drug-
membrane lipid interactions are inevitable and membranes are not amorphous and 
unreactive structures [111].  
There are two main types of conventional membranes model, an intact vesicle 
platform (three dimensional membrane models) and a planar lipid arrangement (two 
dimensional membrane models) [183]. Conventional membrane models systems include 
Langmuir monolayers, lipid vesicles (or liposomes), micelles and supported lipid bilayers 
[184-185]. These conventional membrane model systems, sometimes described in the 
literature as artificial membrane models, offer the possibility of manipulation of the lipid 
content, salt concentration, pH and other factors in order to mimic the composition, 
curvature, electrostatic potential or permeability properties of the chosen biological 
membranes [186]. 
Alternatively to the conventional, more sophisticated membrane models as sensing 
platforms consisting in cell-derived membranes and miniaturized lab-on-a-chip 
architectures are used to study membranes that contain specific receptors for instance 
[181],[183].  
 
2.6.1. Liposomes 
The discovery of liposomes took place in 1965, when Bangham and coworkers 
showed evidence of the phospholipids self-assembly, with the phospholipid tails orienting 
towards each other to form one or more bilayers entrapping an aqueous pool, when in an 
aqueous compartment [187-188]. This discovery confirmed earlier studies that claimed 
that all plasma and intracellular membranes are based on phospholipid bilayers, and 
encouraged the use of liposomes as the main model system to study the physicochemical 
and other properties of biological membranes [189-190]. Liposomes are closed vesicles 
commonly formed by hydration of a dry phospholipid film above the Tm. In the 
conventional technique (Figure 28), the lipid vesicles are prepared by dissolving the 
chosen lipids in organic solvents (a 3:1 mixture of chloroform:methanol), being the 
solvents evaporated under a vacuum to form thin films of lipids at the bottom of a round-
bottom flask. Then, the dried lipid films are rehydrated in the aqueous buffer in order to 
Theoretical	  Background	  
	   43	  
form the lipid vesicles. The suspension obtained is vortexed until complete dissolution of 
the lipid film [111]. The resulting structures are multilamellar vesicles (MLVs), which 
consist of many concentric bilayers in a single particle. MLVs can be further processed by 
sonication or by extrusion through a filter to form liposomes with a single membrane 
bilayer [190-191]. Unilamellar vesicles (ULVs) can be further classified into small 
unilamellar vesicles (SUVs) and large unilamellar vesicles (LUVs) [36]. Alternatively to the 
conventional method, novel techniques to prepare liposomes offer advantages, such as 
the possibility to prepare lipid vesicles without using volatile organic solvents or detergents 
[192], such as the polyol dilution method [193] and the bubble method [194]. 
 
Figure 28. Schematic representation of a conventional method (i.e. lipid film hydration) of 
liposomes preparation. Adapted from [195]. 
 
The liposomes diameter size ranges from 20 nm to several hundreds of 
nanometers, whereas the thickness of the phospholipid bilayer membrane is 
approximately 4-7 nm. Their classification is generally based upon their size and number 
of lipid bilayers (Figure 29). MLVs comprise several lipid bilayers separated by aqueous 
spaces, and their diameter varies between a few hundred to thousands of nanometers. 
SUVs show a diameter inferior to 100 nm and LUVs a diameter superior to 100 nm 
[191],[196].  
Additionally, during the last years liposomes have also attracted great interest as 
efficient carriers for drugs, diagnostics, vaccines, nutrients and other bioactive agents 
[192].   
 
 
 
 
 
Dry Lipid Film Swelling 
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Figure 29. Liposomes of different size and number of lamellae. 
2.6.2. Langmuir Monolayers 
The history of the monolayers is very old and dates back to the period of the 18th 
century BC in Babylon, where pouring oil on water or water on oil and observing the 
subsequent spreading was considered a superstition dedicated to the Gods. Later, the 
same divination practice was also adopted by the Greeks. The first scientific approach 
towards to the monolayers was undertaken by Benjamin Franklin in 1744 and thereafter 
more extensively by Irving Langmuir, which was awarded with the Nobel Prize in 1932 by 
its contribution in the surface chemistry. Katharine Blodgett also gave a significant 
contribution to the monolayers film and in 1935 demonstrated the sequential transfer of 
monolayers onto the solid substrate to form multilayer films, which are nowadays referred 
to as Langmuir-Blodgett films [197-198].  
The preparation of the Langmuir monolayers is quite simple and consists in the 
spreading of a surfactant (e.g. lipid solution, dissolving the lipid in a organic solvent) and 
use of a syringe to produce a droplet at the end of the needle that touches on the surface 
of the aqueous subphase (Figure 30). After approximately 15 min, the solvent evaporates 
and a monolayer is formed on the surface of the aqueous subphase. The addition of a 
certain substance (e.g. drug) on the monolayer or in the subphase will be strongly 
dependent of its solubility in the monolayer and the main purpose of the study. 
Additionally, the monolayers are produced in a balance, commonly referred to as a 
Langmuir trough, that consists in a trough usually made up of hydrophobic materials (e.g. 
Teflon) [198]. 
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Figure 30. Schematic representation of the Langmuir monolayers preparation. Adapted from [199]. 
 
In fact, the Langmuir monolayers are considered the most simple membrane model 
systems, being basically half a membrane [110]. Although, they are less appropriate to 
study transmembrane processes, they are most suited to mimic processes at membrane 
surfaces and are more similar to the rearrangement of several biological membranes (e.g. 
PS, gastric mucosa) [200-201]. Langmuir monolayers as membrane model systems allow 
controlling several parameters such as lipid composition, subphase, and temperature. In 
addition, lipid monolayers are very well-defined, stable and bidimensional systems with 
planar geometry and for the above-mentioned reasons are frequently used to mimic 
membranes [111],[202]. 
 
2.6.3 Membrane Models Commonly Used to Mimic Eukaryotic, 
Prokaryotic Cell Membranes and Pulmonary Surfactant  
 
The most common membrane models used to mimic human and bacterial plasma 
membranes are three-dimensional (i.e. vesicles), being the two-dimensional (i.e. 
monolayers) also used.  
To mimic the human plasma membrane, the PCs are generally present, being the 
EPC, DMPC and DPPC the main phospholipids used [203]. Lipid mixtures are also used, 
being the CHOL commonly used associated with the PCs [204]. Phospholipids frequently 
associated with the PCs include among others, PSer, PG [205]. 
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In order to mimic bacterial membranes, the most frequently used lipids are the 
PGs [206]. In addition, mixtures are commonly used, being CL and PE recurrently 
associated with the PGs [207-208]. 
Generally, the in vitro studies use monolayers as the classical model to mimic the 
PS [209]. In the literature, three-dimensional, namely vesicles are also described to mimic 
the PS [209-210]. The models generally include DPPC as the main compound present in 
the PS [210-220]. However, mixtures of DPPC and other lipid surfactants different from 
the previous are also used [35],[221]. Since DPPC stands for 40-45% of the PS 
composition, it is used in higher quantities or even as the only component of the PS 
surfactant model. When present, the other lipid added to DPPC mimics the effect 
produced by the non-dipalmitoyphosphatidylcholine lipids, aiding in the lipid monolayer 
fluidity and influencing, in vivo, DPPC adsorption at the air/water interface [35],[37],[221]. 
Natural PS as Curosurf®, Exofurf®, Survanta® or Alveofact® are also used, being derived 
from animals and therefore more similar to the human PS [209],[215-216],[222]. 
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CHAPTER III 
 
Methods to Evaluate the Antimycobacterial 
Compounds-Membrane Interactions 
 
“Experiments never deceive. It is our judgment that deceives itself because it expects 
results which experiments do not give.” [223] 
 Leonardo da Vinci, 15th century 
 
The transport of antibiotics across the the cell membranes is a biological process, 
often misunderstood because of its complex and dynamic nature [111]. In this regard, 
model lipid membranes, which mimic many aspects of cell-membrane lipids, allow to 
account the passive diffusion across the bilayers, which is the most important process of 
the drug’s permeation, specially in the case of drugs with high lipophilicity, such as RFB 
and analogs [224]. Indeed, drug-lipid membrane interactions allow to predict the 
pharmacokinetic properties, such as absorption, distribution, transport, accumulation, 
metabolization, elimination and hence efficacy [111],[225]. In fact, RFB is administrated 
orally and therefore it must cross biological membranes to be absorbed, distributed, 
metabolized and eliminated from the body [96]. Thus, understanding the role of these 
interactions on the pharmacokinetic properties of the antibiotics is critical for the 
development of more potent antimycobacterial compounds [224]. These interaction 
studies can be of particular interest when applied to novel potential drugs as in the case of 
RFB2 and RFB3, in order to predict their pharmacokinetic properties and understand if 
they have physical chemistry properties that enable them to reach the clinical trials and 
even further, the market. Moreover, these interaction studies can be used to design and 
develop efficient drug delivery systems [111].  
Several biophysical techniques may be used to assess the interaction between 
drugs and membrane models. The drug-membrane interactions techniques employed 
allowed to study the partition of the drug to the membrane models, the location of the drug 
within the lipid bilayers and the influence of the drug on the biophysical parameters of the 
membrane models chosen (Figure 31). 
In this chapter, the biophysical techniques to assess drug-membrane interaction 
studies are discussed. The complete description of the experiments, as well as, the main 
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results and the correlation with the therapeutic and toxic effects are presented with more 
detail in the several sections of Chapter IV. 
 
 
 
Figure 31. Schematic representation of drug-membrane studies. 
 
1. Drugs Transport Through Cell Membranes and Lipophilicity 
Measurements 
 
Drugs transport trough the cell membranes (Figure 32) follows the passive diffusion 
and/or active transport [226]. Passive diffusion may occur through the lipid bilayer 
(transcellular pathway) or through the water-filled pores or tight junctions (paracellular 
pathway). The transcellular diffusion is the main route in the case of the lipophilic drugs. 
The lipophilicity is a complex concept since it covers both nonpolar and polar interactions 
[227]. The lipophilicity of a drug molecule, expressed in terms of the logarithm of octanol–
water partition, coefficient log P, or in the case of ionised molecular species, distribution 
coefficient log D, are important molecular descriptors of the pharmacokinetics properties 
of a drug molecule. Indeed, the lipophilicity affects the absorption, distribution, 
metabolization and elimination (i.e. pharmacokinetics) of a drug, affecting also their 
pharmacodynamic and toxicological properties [228].  
Drug-­‐membrane	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Figure 32. Membrane transport of drugs. Left, the drug (D) partitions into the lipid bilayer of the 
membrane according the log P; Right, the drug transport occurs via carriers that exist in the 
membranes. Adapted from [229]. 
 
Several systems were used since the 20th century to evaluate the lipophilicity of the 
drug. For instance, oil-water, heptane-water and octanol-water among others. The 
octanol–water system is the reference system to evaluate the lipophilicity of a drug, being 
the log P a characteristic constant for a chemical substance [227].  
To reach the market, a drug molecule should have a log P comprised in a certain 
range [230]. A low lipophilicity is associated with a scarce interaction with the biological 
membranes and therefore, low absorption and distribution. On the other side, a high 
lipophilicity is connected with an extensive and unpredictable metabolism, high plasma 
protein binding or accumulation to tissues. In addition, a preferred log P for the 
penetration through biological barriers is also described for the antimycobacterial 
compounds as is pointed to be between 1.3 and 4.1 [231]. In the last years, the octanol–
water system has received a lot of criticism, regarding its limitation to mimic the 
biomembranes environment. This system has a hydrophobic chain with a polar head 
group (hydroxyl), allowing it to account for the hydrophobic and hydrogen bonds 
interactions. The partition coefficient is related with the neutral monomer species, being 
the distribution coefficient the resultant of the ratio of the sum of the concentration of all 
species in octanol to the corresponding concentration sum in water [227]. 
Therefore, alternatives as the partitioning into liposomes and immobilised artificial 
membrane chromatography are gaining support. Because of their structural and 
anisotropic environment similar to the biomembranes, the liposomes constitute a realistic 
analytical system and can mimic closely the cell membranes, providing additional 
information to that obtained with the octanol–water system [232]. In addition, their 
constitution in phospholipids allow accounting for the electrostatic interactions between 
charged drugs and the polar head groups of the phospholipids. Moreover, the 
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conformational changes are also accounted and for instance the binding of a cationic 
molecule to the anionic phosphate anion leads to the repulsion of the positively charged 
quaternary nitrogen towards the water phase and thus, to a “opening” of the polar region 
and a penetration of the drug into the hydrophobic tails [227]. The immobilised artificial 
membrane chromatography consists of monolayers of phospholipids covalently 
immobilized on a silica surface, thus mimicking the lipid environment on a solid matrix 
[226],[233].  
Several software programs can be used to determinate the log P and log D of a 
drug molecule. Nevertheless, their prediction is related to a large error, which is 
associated with the complexity in the inter- and intramolecular interactions and the 
conformational effects involved in partitioning process [227]. 
Active transport of drug molecules through the membrane is outside the scoop of 
this thesis, being although mentioned due to the contextual reasons. The active transport 
is especially relevant in the case of hydrophilic drugs, occurring against the gradient of 
concentrations, and implies their transport by carrier-facilitated transport across the 
membranes [226]. 
1.1. Determination of the Partition Coefficient by UV-Vis 
Derivative Spectrophotometry 
The determination of the partition coefficient (Kp) of a drug may be determined 
from the UV-Vis derivative spectrophotometry technique [234-236]. The mentioned 
technique is based in the interaction of the light (in the range of the UV and Visible, 
respectively 180-400 and 400-750 nm) with the matter (e.g. lipids suspensions) in order to 
perform a quantitative measurement, with the ratio providing the partition of a drug 
between the water and the lipid. It requires the preparation of a series of lipids 
suspensions (e.g. micelles, liposomes) of increasing lipid concentrations, without 
(references) and with a fixed concentration of a drug (samples). Furthermore, the 
absorbance of the samples is measured in the UV-Vis range. In addition, the absorbance 
A, is defined as the log10 of the ratio of the incident to transmitted light beams and since 
both incident and transmitted light are measured in watts it is a unit-less quantity [237]. 
The concentration of the drug tested must be considered regarding its therapeutical 
relevance and needs to agree with the Beer-Lambert law [237]. Nevertheless, because 
the Kp is a ratio, the concentration of the drug should not change the Kp considerably. 
The UV-Vis Derivate Spectrophotometry technique is based on the spectral 
variations presented by the drug in the presence of increasing lipid concentrations [238]. 
The major drawback of this technique is the strong signal arising from the lipids, which is 
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caused by the vesicles scattering [239]. This scattering corresponds to the Rayleigh light 
scattering, being specially pronounced in the UV region [240]. However, this might be 
overcomed by the subtraction of the lipid blank suspensions (i.e. references) to the 
samples and the derivation of the data.  The use of derivation generally goes to the third 
or even fourth, being a commitment between the signal and the noise [239-240]. 
Therefore, derivative spectrophotometry allows to eliminate the effects of the residual 
background signals without need to prior separation procedures and permit the 
improvement of the resolution of overlapping spectra by the derivation [241-242]. The 
presence of the isosbestic points, (i.e. specific wavelength where the samples have the 
same absorbance) prove two important features, that the residual background signal 
effects were entirely eliminated and that the drug exists in two states, in the water and 
lipid bilayer phases [243]. In addition, with increase of the lipid concentrations the 
absorbance shift for lower or higher wavelength is also indicative of the drug’s partition. 
Therefore, a shift for lower wavelength (hypsochromic shift) is caused by the increase of 
the polarity in the drug molecules’s surrounding. On the other hand, a shift for higher 
wavelength (batochromic shift) suggests a decrease of the polarity of the drug’s 
surrounding [244]. 
The Kp is generally calculated from the second and third derivative spectra at the 
wavelengths where the scattering is eliminated, by fitting Equation 1 to the experimental 
data (Dt versus [L]) using a non-linear least-squares regression method where the 
adjustable parameter is the partition constant, Kp (in molar) [232],[235],[242]: 
 
            (1)  
 
In this equation, D is the second or the third derivative intensity (D=(dnAbs)/(dλn)) obtained 
from the absorbance values of the total concentration of the drug (DT), drug distributed on 
the lipid membrane phase (Dm), drug distributed in the aqueous phase (Dw), [L] is the lipid 
concentration and Vm is the lipid molar volume [242].  
The mathematical treatment of the absorbance data was performed using a 
developed routine application for Microsoft Excel®, designed as Kp calculator [245], being 
the Kp represented several times by the log D (for ionized drug) or log P (for non-ionized 
drugs), which consists in the ratio between the Kp and the Vm, being an dimensionless 
unit. 
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2. Evaluation of Drug’s Membrane Location 
The knowledge regarding the drug’s location within the lipid bilayers may give useful 
information about their pharmacokinetics properties (e.g. understand if the drug diffuse 
across the lipid bilayer) and mechanisms of action, since the drug’s location may 
compromise the integrity of the biological membranes, affecting the biophysical 
parameters and promoting a membrane disturbance or even disruption [224]. 
The drug’s location within the lipid bilayer may be assessed by direct or indirect 
techniques. The direct techniques comprise among others, X-ray, neutron diffraction, 
nuclear magnetic resonance (NMR) and infrared spectroscopy (IR) [246]. Indirect 
techniques generally require the use of fluorescent probes with a well know location with 
the lipid bilayers. The fluorescence quenching (i.e. deactivation of the probe’s 
fluorescence induced by the drug) is a mean to study the drug relative location within the 
lipid bilayer, being the quenching much more higher the nearer the drug’s location to the 
probe [247-248]. 
 
 
2.1. Steady-state Fluorescence Quenching 
 
The location of RFB and analogs in the membrane models was studied by 
fluorescence quenching. The fluorescence quenching is a sensitive method to determine 
the drug’s relative location in the lipid bilayer [249]. The former technique involves the 
utilization of fluorescent probes. The probes should exhibit a constant fluorescence and 
must be used in appropriate concentrations in order to not perturb the lipid [250]. Thus, in 
the experiments included in this thesis the probes chosen, namely, 1,6-diphenylhexatriene 
(DPH) and propionic acid-1,6-diphenylhexatriene (DPH-PA) (Figure 33),  have a negliglbe 
perturbing effect on the lipid bilayers in the concentrations used (i.e. 1:300 molar ratio 
probe:lipid) [251].  
 
Figure 33. Chemical structures of DPH and DPH-PA. Adapted from [252-253]. 
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DPH is a hydrophobic rod-shaped probe that prefers the hydrophobic acyl chain 
region of the lipid bilayers [254]. Therefore, it is widely used in experiments to study the 
membrane fluidity and ordering of the lipid [255]. DPH-PA is a more polar probe than DPH 
due to the propionic acid group, [256-257] being therefore anchored to the surface of the 
membrane in the phospholipids polar head groups [258]. 
The fluorescence quenching of a membrane bond fluorophore provides a measure 
of its accessibility to the drug (quencher) and can be related with the concentration of the 
quencher by the Stern-Volmer equation [259]: 
!!! = 1 + 𝐾!" 𝑄 !                                                                                  (2)  
 
In this equation I0 and I are the fluorescence intensities in the absence and presence of 
the quencher, respectively; KSV is the quenching constant, called the Stern–Volmer 
constant;   𝑄 ! is the concentration of the quencher that is able to partition the membrane. 
In fact, the extrinsic fluorophores used in quenching studies are inserted into the lipid 
bilayer and consequently the accessibility of the drug to the fluorophores should be 
determined using the fraction of drug molecules that are able to partitioning with the lipid 
bilayer. The 𝑄 ! is calculated from the total drug concentration ([Q]T) and from the drug’s 
partition coefficient (Kp), as described by the Equation 3 [249]: 
 𝑄 ! = !! ! !!!!!!(!!!!)                                                                       (3)             
 
where αm is the volume fraction of the membrane phase (αm = Vm/VT; Vm and VT represent 
the volumes of the membrane and water phases, respectively). In addition, the 
fluorescence intensities should be corrected in order to eliminate the “inner filter effect”, 
using the Equation 4. The former effect happens if the drug absorbs at the wavelength of 
excitation of the fluorophore, decreasing the effective intensity of the exciting light beam 
and thus decreasing the measured fluorescence intensity [249]. 
                                                                             (4)  
 
 
where Icorr is the corrected fluorescence intensity, I the experimental fluorescence, AQ and 
AF, the absorbance of the sample in the absence and presence of the quencher [249].  
As above-mentioned, the fluorescence quenching study is useful to predict the 
relative location of the drugs within the lipid membrane. Therefore, the use of different 
Icorr = I
AQ
AF
1−10−AF
1−10−AQ
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probes with different membrane locations allows to infer the preferential location of the 
drug within the lipid bilayer, being the higher KSV value obtained for a certain probe, 
indicative of a closer proximity of the drug to that probe in comparison to the other. In 
addition, high KSV values obtained for probes located in the deep regions of the lipid 
bilayer, suggest the accessibility of the drugs to the hydrocarbon regions and the ability to 
penetrates the membrane lipid bilayer [249]. 
 
2.1.1. Fluorescence Quenching Mechanism 
 
A huge variety of molecular interactions may result in fluorescence quenching, 
including excited-state reactions, molecular arrangements, energy transfer, ground-state 
complex formation, and collisional quenching [249]. Fluorescence quenching mechanisms 
are usually categorized into dynamic and static quenching by different mechanisms 
(Figure 34) [260]. For both static and dynamic quenching, the quencher and the 
fluorophore should be in contact. The collisional or dynamic quenching implies the 
diffusion of the quencher to the fluorophore during the lifetime of the excited state [249]. 
Upon contact, the fluorophore returns to the ground state, without emission of a photon. 
On the other hand, the static quenching, the quencher and fluorophore form a complex, 
being this complex nonfluorescent [249]. When this complex absorbs light, immediately 
returns to the ground state without emission of a photon [249]. 
In order to distinguish the fluorescence quenching mechanism, the fluorescence 
lifetimes is the most appropriate method. In addition, to definitely prove the type of 
fluorescence quenching, studies at several temperatures must be performed. In the case 
of dynamic quenching, higher temperatures result in faster diffusion and hence larger 
amounts of collisional quenching [249]. On the other side, in the case of static quenching 
higher temperature will result in the dissociation of the weakly bound complexes, and 
consequently smaller amounts of static quenching (Figure 34) [249]. 
The Equation 5 describes the mathematical formalism beyond the collisional 
quenching of fluorescence [249]: 
   !!! = 1 + 𝐾! 𝑄 !                                                                                    (5)  
 
The 𝐾! corresponds to the dynamic portion of the quenching and is determined by 
the lifetime measurements. That is, 𝜏! /τ = KD. The 𝜏!  is the lifetime of the fluorophore in 
the absence of the quencher and τ is the lifetime of the fluorophore in the presence of the 
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quencher. The observation of a linear Stern-Volmer plot does not prove that collisional 
quenching of fluorescence has occurred since the static quenching also results in Stern-
Volmer linear plots [249]. The Equation 6 describes the mathematical formalism beyond 
the static quenching of fluorescence [249]: 
 
 !!! = 1 + 𝐾! 𝑄 !                                  (6) 
The 𝐾!  corresponds to the static portion of the quenching. In the case of the static 
quenching the 𝜏! /τ =1.  Thus, in the static quenching the lifetime remains the same since 
only the fluorescent molecules are observed and the uncomplexed fluorophores have the 
unquenched lifetime 𝜏!  [249]. 
 
 
 
 
 
 
 
Figure 34. Comparison of dynamic and static quenching. Adapted from [249]. 
 
Additionally, the bimolecular quenching constant (Kq) is a fundamental parameter 
that reflects the efficiency of quenching or the accessibility of the probes to the drug, and 
is calculated as follows (Equation 7) [249]: 
 𝐾! = !!"!!                                                                                                                     (7)  
 
2.1.2. Deviations from the Linear Stern-Volmer Plots 
 
The linearity of the Stern-Volmer plot indicates that only one type of quenching (i.e. 
collisional or static) occurs. However, negative and positive deviations from the Stern-
Volmer equation are frequently observed [249]. 
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Negative deviations to the Stern-Volmer linearity generally indicate the presence of 
fractions of fluorophore with different accessibility to the quencher. This occurs commonly 
in proteins because due to the tryptophan residues, which act as fluorophores and are 
positioned in distinct environments and consequently have different accessibility to the 
quencher [249],[261].  
Positive deviations from the Stern-Volmer equation are commonly observed when 
the extent of the quenching is large. The combined static and dynamic quenching may 
result in an upward curvature to the Stern-Volmer non-linear plot. Indeed, the 
fluorescence quenching may result from both dynamic and static quenching. In those 
cases, after the determination of the dynamic component, the static contribution may be 
found by linearization of the following second order equation (Equation 8) in [Q]m [249]: 
 !!! × !!!!![!]! = 1 + 𝐾![𝑄]!                                              (8)  
 
In addition, the positive deviation of the Stern-Volmer plots can also be interpreted 
in terms of a “sphere of action” static quenching model [249],[260]. According to this 
model, instantaneous quenching occurs if the quencher molecules are adjacent to the 
fluorophore at the moment of excitation. When the fluorophore and the quencher are 
closer there is a high probability that the quenching will occur before these molecules 
diffuse apart. As the quencher concentration increases, the probability also increases, 
because the quencher is within the sphere of action of the fluorophore at the moment of 
excitation. Therefore, only a certain fraction of the excited fluorophore is quenched by the 
Stern-Volmer collisional mechanism. Moreover, this model assumes that if the quencher is 
located inside a spherical volume (V) adjacent to the fluorophore, the probability for the 
quencher to be inside this volume at the time of excitation depends on the volume itself 
and on the quencher concentration ([Q]m), as it is described by the modified Stern-Volmer 
equation (Equation 9) [249-250]: 
 𝑙 𝑛 !!!!!! = 𝑉 𝑄 !                                                                                  (9)  
 
2.2. Time-Resolved Fluorescence Quenching 
 
Time-resolved measurements are widely used in fluorescence spectroscopy to 
monitor molecular interactions and motions that occur in the picosecond-nanosecond time 
range, being especially useful in the analysis of the biomolecular structure and dynamics 
Methods	  to	  Evaluate	  the	  Antimycobacterial	  Compounds-­‐Membrane	  Interactions	  
	   57	  
[262]. Time-resolved fluorescence quenching provides additional information to the 
steady-state fluorescence. For instance, time-resolved fluorescence quenching allows to 
distinguish between static and dynamic quenching through the fluorophore lifetime 
measurements [249]. The lifetimes measurements may be determined using pulse 
fluorimetry or phase-modulation fluorimetry techniques [223]. Pulse fluorimetry uses a 
short exciting pulse of light and yields the d-pulse response of the sample, convoluted by 
the instrument response. The technique used in this work, namely, phase-modulation 
fluorimetry uses modulated light at variable frequency and provides the harmonic 
response of the sample, which is the Fourier transform of the d-pulse response [223]. In 
this technique, a sinusoidally modulated light at high frequency excites the sample. 
Regarding the existence of a lag time between absorption and emission, the emission is 
delayed in time relatively to the modulated excitation. The mentioned delay is measured 
as a phase shift φω between the excitation and emission, where ω is the modulation 
frequency in radians/s. Additionally, the finite time response of the sample results in 
demodulation of the emission by a factor mω. The finite lifetime of the excited state avoids 
the emission from exactly following the excitation, which results in a decrease in the peak-
to-peak amplitude of the modulated emission, being measured relatively to the modulated 
excitation (Figure 35) [263]. 
 
 
 
 
 
 
Figure 35. Frequency-domain lifetime measurements. In this example the assumed decay time is 5 
ns and the light modulation frequency is 80 MHz. Adapted from [263]. 
The phase shift and modulation of the emission depend on the relative values of the 
lifetime and on the light modulation frequency, being the dependence of the phase angle 
φ and modulation m on the light modulation frequency used to determine the intensity 
decay of the sample. Moreover, the phase angle and modulation are measured over a 
wide range of frequencies (Figure 36). The frequency response of the sample used in this 
work was in the 0-200 MHz range. The increment in the light modulation frequency is 
accompanied by the phase angle rises from 0 to 90º [263].  
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Figure 36. Frequency-domain example. The phase angle increases and the modulation decreases 
with increasing modulation frequency. Adapted from [263]. 
 
The shape of the frequency response is determined by the number of decay times 
displayed by the sample. In the case of a single exponential decay, the frequency 
response is simple, being the phase and modulation related to the decay time (τ) by the 
Equations 10 and 11 [263]: 
 
tωϕω =tan                                      (10)  
2
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−
+= τωωm                             (11)  
 
 
Nevertheless, the majority of the samples display more than one decay time. In those 
cases it becomes necessary to measure the phase and modulation values over the widest 
possible range of modulation frequencies. Therefore, the lifetime of the multi-exponential 
fluorophores is defined by (Equation 12) [263]: 
 
       (12)  
 
 
being N, the total number of frequencies. Therefore, the number of data points is twice the 
number of frequencies, so that the number of degrees of freedom is υ = 2N – p (p = 
number of fitted parameters). The subscript c is used to indicate calculated values for 
assumed values of the fractional contribution of the component i to the total lifetime (fi) 
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and τi. The σф and σM are, respectively, the uncertainties in the phase and modulation 
values [263]. 
 Finally, a fitting procedure (nonlinear least-squares) is applied to the data, being 
obtained a χ2, that if comprised between 0.8-1.2 is indicative of a good fit [223],[263].  
 
3. Biophysical Modifications of the Membrane 
The majority of the drugs are able to directly or indirectly influence the biophysical 
membrane properties, by means of the interactions with proteins and/or phospholipids 
[264-265]. A large number of drugs affect the fluidity of the membranes, which is a 
parameter fundamentally linked to the membrane structure. In fact, the fluidity is a critical 
property of the membranes that interferes with the activity of the membrane proteins and 
modulates the membrane permeability [266]. Moreover, changes in the membrane fluidity 
can affect the receptor and enzyme activity and influence the drugs ability to pass through 
the membrane, which in turn can affect their efficacy. In fact, the fluidity is closely 
dependent of the biophysical parameters Tm, phospholipids packing order and 
cooperativity of the membranes [267]. 
Several biophysical techniques can be performed in order to obtain a detailed analysis 
of the complexity of membrane dynamics and thermodynamics in the absence and 
presence of drug molecules. Thus, in this work, several techniques were employed, 
providing a detailed and complementary description of the modifications in the membrane 
biophysical properties caused by RFB and analogs. 
It is estimated that more than 150 different methods to study the biophysical 
parameters of the membrane models exist [267]. For that reason, in this thesis only the 
carried out methods are going to be described. 
3.1. Dynamic Light Scattering 
Dynamic light scattering (DLS) exploiting the count rate is a reliable, simple and 
reproducible technique to determinate the biophysical parameters of the membrane as the 
Tm and the cooperativity. In addition, despite the Tm, this method also allows the 
determination of also sub-transitions involving under-phases [267-268]. The alteration in 
the measured scattering intensity reflects changes in the optical properties of the material. 
Thus, discontinuity in the mean count rate (average number of photons detected per 
second) as the temperature changes corresponds to an alteration in the optical properties 
of the studied material (i.e. transition from the initial state to another one). Data as the 
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normalized mean count rate versus the temperature after being collected may be fitted 
using the Equation 13 [267]: 
                                                                   (13)    
where rs is the average count rate, T is the temperature (°C), p1 and p2 correspond to the 
slopes of the straight lines at the beginning and at the end of the plot, and rs1 and rs2 are 
the respective count rate intercepting values at the y axis. From the experimental data it is 
possible to calculate the cooperativity (B) and the midpoint of the phase transition, which 
corresponds to the Tm. In addition, the Tm may be calculated from the slope and the 
inflection point of the data fitted to sigmoid curves of count rate (rs) versus temperature (T) 
(Figure 37) [232],[250],[267].  
The experimental procedure to determine the influence of drugs on the biophysical 
parameters of the membrane models is very simple and does not require the use of an 
exogenous probe. Therefore, the effect of a certain concentration of a drug is tested using 
the three dimensional membrane model with a lipid concentration that allows to obtain a 
count rate included in the range of the count rate indicated for the equipment [267]. 
Moreover, parameters as the temperature intervals, number of measurements to be made 
at each step after equilibration time, temperature range and scan speed should be 
adjusted to obtain the desired accuracy level [267]. 
 
 
 
 
 
 
 
 
 
Figure 37. Schematic representation of the process of phase transition as propagation of a physical 
macroscopic property (δ0) (e.g. count-rate) and corresponding curve as property vs. temperature. 
Adapted from [267]. 
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3.2. Steady-state Anisotropy 
Fluorescence polarization methods, and specifically anisotropy provide useful 
information on the molecular mobility, fluidity of a medium, lipid’s order parameter, and 
cooperativity [223]. 
The fluorescence can be considered as the result of three independent sources of 
light polarized along three perpendicular axis Ox, Oy, Oz, being the Ix, Iy, Iz the intensities of 
these sources, and the total intensity the sum of all these sources. The values of the 
intensity components depend on the polarization of the incident light and on the 
depolarization processes. In addition, the excitation light may be vertically polarized, 
horizontally polarized or even unpolarized (i.e. natural light) [223]. In the particular case of 
the steady-state determination the light must be vertically polarized, being the 
fluorescence intensities measured with the emission polarizer oriented parallel (III) and 
perpendicular (I⊥) to the excitation polarized. The steady-state anisotropy (rss) is then 
defined by the following relationship between the relative intensities of fluorescence 
(Equation 14) [223][249]: 
                                                                                 (14)  
 
being G an instrumental correction factor given by the ratio of the sensitivities of the 
detection system for vertically and horizontally polarized light (Equation 15) [249]:                                                                                                         (15)  
  
The experimental procedure for the steady-state anisotropy is very similar to the 
former method (DLS), however with an additional requirement, namely an extrinsic 
fluorophore inserted within the lipid bilayer. In a highly ordered lipid bilayer (i.e. gel 
phase), the movement of the probe is extremely restricted and a parallel orientation of the 
fluorophore molecules to the vertical excitation polarizer is induced. Thus, the molecules 
of the fluorophore emit polarized light since they remain immobile during the lifetime of the 
excited state. On the other hand, if the environment surrounding the fluorophore is fluid, 
the free rotation of the fluorophore molecules pushes a random fluorophore orientation, 
resulting in a decrease in the emission of polarized light. The explanation for this decrease 
is based on the lack of alignment with the vertical excitation polarizer [249]. 
From the experimental data obtained it is possible to determine the cooperativity 
(B) and the Tm, calculated from the slope and the inflection point of the data fitted to 
rss =
I|| −GI⊥
I|| + 2GI⊥
G = I⊥I||
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sigmoid curves of steady-state anisotropy (rs) versus temperature (T) data (Equation 16) 
[249].  
 
     (16)  
 
The rs1 and rs2 are the respective steady-state anisotropy intercepting values at the y axis, 
T is the temperature (°C) and p1 and p2 correspond to the slopes of the straight lines at 
the beginning and at the end of the plot.  
In addition, from the values of anisotropy it is also possible to determine the 
limiting value of anisotropy (𝑟!), which reflects the restriction of movement of the probes. 
This value is obtained using Equation 17, which is only valid for values of rss between 0.13 
and 0.28 [269]: 
                                                                   (17)  
 
The order parameter can be calculated from the Equation 18: 
   𝑠 = 𝑟!/                                                                                                 (18)  
 
where  (fundamental anisotropy) is the fluorescence anisotropy in the absence of any 
rotational motion of the probe and 𝑟! (limiting anisotropy). 
 Steady-state fluorescence anisotropy measurements allow the quantification of the 
fluidity gradient across bilayer structures, which may be used to understand the 
mechanism of action. In the case of RFB and RFB2 the fluidity seems to be slightly 
affected in the human membrane model, particularly in comparison in with the bacterial 
membrane model, which suffers a decrease of the fluidity in the presence of the 
antimycobacterial compounds. Therefore, the increment of the phospholipid order may be 
responsible for the impairment and disruption of the bacterial membranes with consequent 
cell death [270-271].
 
3.3. X-Ray Scattering 
 Historically, X-rays were discovery in 1895 by Röntgen (nobel prize in 1901) and 
so named because of their unknown nature [272]. The X-rays are invisible and possess 
an extraordinary ability to penetrate through the human body and opaque objects. 
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Radiographies were then developed, putting a source of X-rays on one side of a certain 
object and a photographic film on the other [273]. Later in 1992, the exact nature about 
the X-ray was established with the von Laue's (nobel prize in 1914) discovery that the 
diffraction caused by a crystal is close related with its structure [273-274]. 
 Currently, the X-ray scattering techniques are applied to several fields, playing a 
major role in the elucidating of the drugs effects on the structural details of biological 
membrane models [275]. In fact, X-ray scattering experiments constitute a valuable 
approach to get an insight into the membrane properties, since it has many advantages 
as the fact of being non-invasive and label-free [271]. Moreover, these techniques applied 
in the field of phospholipid membrane models allows to investigate the influence of the 
drugs on the phase of the lipids [276]. 
The X-ray scattering measurements are preferentially made on synchrotron and 
lab-based X-ray sources [276]. These experiments are based on the measurement of the 
scattered intensity as a function of scattering angle relative to the incident beam. In 
addition, the scattered intensity is expressed in terms of the scattering vector, q, which 
represents the modulus of the change in momentum of the scattered radiation (Equation 
19) [276]: 
 
q = 4πsenθ
λ
                                     (19) 
 
 
where λ is the wavelength of the scattered radiation and 2θ is the scattering angle relative 
to the incoming beam. The Braggs peaks exhibit an angular position, which indicates a 
periodic spacing within the sample, and may be used to measure the periodic spacings 
within the sample. Additionally, the mentioned distances, d, of the spacing can be 
calculated using the Bragg equation and the angular position of for example, the first 
order diffraction peak (Equation 20):   
                   (20)  
 
where n is the order of the reflection and therefore a positive integral number (n = 1 for 
first order). For the first order scattering peak, the Equation can be simplified and rewritten 
as (Equation 21) [276]: 
 
d = 2πq                                              (21) 
 
( )θλ dsenn 2=
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Samples as the MLVs with lipid bilayers oriented randomly show strong reflections in 
comparison with unilamellar vesicles. For that reason, MLVs are generally used due to 
their possession of a positional order. Vesicles with only one lamella, as the LUVs and 
ULVs do not have a positional order normal to the plane of the bilayer, which results in 
diffuse peaks and difficult to be analysed [271]. Therefore, the experimental procedures 
used involved the preparation of MLVs of several phospholipids without and with the 
tested drug in several concentrations [277]. 
The scattering data obtained is radially symmetric but may be transformed and 
plotted as intensity versus the scattering vector, q or the s (lamellar spacing) [276]. 
Furthermore, X-ray scattering is mainly classified into small-angle X-ray scattering 
(SAXS) and wide-angle X-ray scattering (WAXS), depending on the scattering angle 
[278]. 
 
3.3.1. Small-Angle X-Ray Scattering 
	  
SAXS is nowadays one of the most powerful methods for probing the 
nanostructures of self-assembled systems [279-280]. With the development of 
sophisticated third-generation synchrotrons in the late 1980s, SAXS experiments were put 
into practice with the intention to study the temperature-driven transitions in lyotropic 
liquid-crystal systems [279].  
SAXS corresponds to the X-ray scattering at the small angle (< 2.3º) region, 
providing information in the size range of nanometers [278]. In the field of phospholipids, 
SAXS is typically applied to obtain the distances between the lipid bilayer plus water layer 
(Figure 38).  
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Figure 38. Schematic of the diffraction patterns obtained according different lipid phases and the 
corresponding distances measured by SAXS and WAXS. Adapted from [281]. 
In addition, with SAXS measurements it is possible to assign different lipid phases 
through the relation between the positions of the diffraction peaks: lamellar 
(1:1/1:2/1:3/1:4/...), cubic (1:1/1:√2/1:√3/1:√4/1:√5/1:√6/1:√8/…), and hexagonal 
(1:1/1:√3/1:√4/1:√7/...). The Lorentzians fitting is applied to the Bragg peaks in order to 
obtain the precise position of the peaks and the full width at half maximum (FWHM). The 
FWHM is required to calculate the correlation length (ξ) between the lipid bilayers, through 
the Equation 22: 
 
                                                      (22)  
 
The ξ is a measure of the correlation between the bilayers. If the correlation is 
high, it indicates that the frequency of appearance of that d is also high, i.e., a large 
number of bilayers present in the same long-range distance, d (or thickness) determined 
by SAXS [282].  
FWHM
π
ξ
2
=
SAXS: 
distances lipid 
bilayer+water 
layer 
WAXS: distances between two 
phospholipid head groups 
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3.3.2. Wide-angle X-Ray Scattering 
WAXS is used to obtain information on sub-nanometer scale structures, such as 
the lipid packing [278]. In addition, in order to determinate the short-range distances (d 
<10 Å) a wide-angle detection is required with values of θ of the order of 5 to 180 ° [277]. 
At temperatures below the chain-melting transition, where the hydrocarbon chains of 
membrane lipids adopt ordered states, the WAXS measurement result in well-defined 
Bragg peaks [283]. At temperatures above the Tm the hydrocarbon chains of the 
phospholipids are melted and therefore a diffuse Bragg peak appears. The Bragg peaks 
assume different features according to the phospholipids packing. Thus, the packing may 
be hexagonal or pseudo-hexagonal. In addition, the symmetry of the chain subcell 
depends on the specific lipid phase (Figure 39). A distorted hexagonal lattice (pseudo-
hexagonal), with two nearest neighbours, is found in the Lβ’ gel phase. On the other hand, 
hexagonal lattices, in which a lipid chain has six nearest neighbours, is found in the Lβ and 
Pβ’ gel phases [284]. The Lorentzians fit is also applied to the Braggs peaks obtained by 
WAXS measurements, which allows to obtain the s, essential to determinate the distances 
between the polar head groups of the phospholipids (Figure 38). In addition, the FWHM is 
also calculated, allowing to determinate the correlation between the phospholipid head 
groups. If the correlation is high, it suggests that the frequency of appearance of d 
(distance between the phospholipid head groups, being a measure of the phospholipid 
packing) is high, and a large number of phospholipids present the same short-range 
distance, d [282]. 
 
 
 
 
 
 
 
Figure 39. Hydrocarbon chain packing symmetries and the corresponding WAXS patterns. 
Adapted from [284-285]. 
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4. Surface Pressure-Molecular Area (π-A) Isotherms 
The surface pressure-molecular (π-A) isotherm corresponds to a plot of the surface 
pressure variation with the area available to each molecule on the aqueous subphase 
surface. The π-A isotherms give valuable information about the influence of the drugs in 
the monolayers lipid phases and the phase transitions, which are both dependent on the 
temperature, the pressure, and the pH [286],[287]. Monolayers of various phospholipid 
compositions at the air–water interface have been intensively used to understand the 
interactions of the drugs with the alveolar lining layer that exists in the lungs [288]. The 
interactions of the etiologic agent of TB, MTb with the PS were performed at the air-water 
interface, using monolayers of MAs to mimic the presence of the bacteria in the alveolar 
lining layer. In addition, the plasma membranes were used to understand the relationship 
between the structure and effect of RFB and analogs in the biological membranes. The 
monolayers were prepared as above-mentioned in the theoretical background chapter. 
The presence of a monolayer in the air/water interface causes a differential interfacial 
tension between the surface with the presence of the surfactant (γm) and the clean surface 
(γ0), being this difference, the surface pressure (π), which can be measured by the 
Wilhelmy plate technique, Thus, by sliding the barriers across the interface, the monolayer 
is compressed, which results in an increase of the surface pressure. Knowing the number 
of molecules present at the interface, the surface pressure can be related to the average 
area per molecule and the surface pressure isotherms can be plotted until the 
compression on the monolayer is such that it collapses. 
From the Langmuir isotherms it is possible to distinguish various phases of the 
monolayer (Figure 40). For instance, in the case of the PCs such as DPPC, during 
compression the monolayer changes from a state where the molecules are far apart and 
the interactions are practically negligible, “gaseous’ monolayer” (G), to a “liquid-expanded” 
(LE) and posteriorly to a “liquid-condensed” (LC), distinguishable by the proximity of the 
surfactant molecules. A small reduction in the area per molecule leads the monolayer to 
the “solid” (S) state, where the amphiphilic molecules are tightly packed, being the 
hydrophobic tails aligned in parallel to the interface air/water [289]. Furthermore, with the 
monolayer compression the collapse is reached (a plateau appears) and a break out of 
the molecules occurs, which may induce a different rearrangement (e.g. micelles, 
multilayers). The transitions between the phases are not always distinct and often more 
than one phase may be present [289-290]. 
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Figure 40. Schematic example of π–A isotherm, exhibiting a variety of phases which can occur. G: 
gaseous, LE: liquid-expanded, LC: liquid-condensed, and S: solid. Adapted from [197]. 
 
Several important parameters can be acquired using the pressure-molecular area 
(π-A) of the Langmuir isotherms, namely the collapse pressure (πcollapse), the limiting area 
per lipid molecule in the compressed state (Amin), hysteresis, and compressibility [291].  
The πcollapse corresponds to the beginning of a plateau region in the isotherm, where 
the surface pressure remains constant even with the decrease of the area, and is an 
indication of the monolayer stability [292]. 
The Amin corresponds to the mean area occupied by one molecule of lipid in the 
surface layer just before the collapse. It indicates both the molecular packing and the 
interactions between the monolayer components [293-294].  
The hysteresis is generally acquired by consecutive measurements of monolayer 
compression/decompression isotherms and corresponds to the difference between 
compression and decompression areas [295-296]. 
It is well-known that the rheological properties of a monolayer can be obtained on 
the basis of the compressibility calculation. Indeed, the change of the surface tension with 
the area in a liquid film can be attributed to its interfacial elasticity. The compressibility of 
the monolayers can be determined using the Equation 23 and 24 [286],[291]: 
   Cs-­‐1  =  -­‐A  (dπ/dA)                                                                          (23)      K  =   !!!!!                                                                                                                (24)  
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where Cs-1 is the elastic modulus, A is the area per lipid molecule, π is the surface 
pressure, and K is the compressional modulus. The Cs-1 describes the relationship 
between the surface pressure increase and the area per molecule decrease. A higher 
value of Cs-1 (lower of K) is indicative of a less compressible monolayer and therefore a 
more ordered monolayer. 
The isotherms are not always reproducibility, being their shape different from the 
expected (e.g. phase transitions are not observed, πcollapse with a different value than the 
expected). The major sources of experimental errors include, impurities in the monolayer, 
impurities in the subphase or in the trough, the solubility of the monolayer material, drifts 
in the surface pressure measuring system, water level alteration caused by evaporation, 
leakage through the barrier, surface density of monolayer material alteration by spreading 
of different amounts and/or excess of materials [292].  
The application of other techniques to the Langmuir isotherms as the optical 
microscopy, specially Brewster angle microscopy (BAM), the synchrotron X-ray diffraction 
at grazing incidence (GIXD) and the infrared reflection-absorption spectroscopy (IRRAS) 
allowed a detailed characterization of drug-membrane interactions [288]. 
 
5. Brewster Angle Microscopy 
BAM, a microscopy tool introduced in 1991 [297], permits the morphological 
observation of the dynamic process of monolayer compression at the air-water interface 
[296],[298]. The main advantage of BAM is that the morphology of the monolayers at the 
air/water interface is visualized without the need of probes as it happens in the 
fluorescence microscopy [299].  Thus, BAM is a powerful technique that allows the 
visualization of the two-dimensional organization of the monolayers, including the size and 
shape of the lipid domains [300]. BAM allows the identification of the phase transitions of 
a monolayer by the appearance of lipid domains. The lipid domains are attributed to the 
reflection caused by alkyl chains and the polar headgroups [297]. In addition, BAM gives 
information about the fluidity of the monolayer in relation to the geometry of the domains 
observed at the air-water interface. Therefore, the contrast in the BAM images results 
from of the local differences in the monolayer refractivity index, caused by differences in 
the local molecular density or packing. In the BAM images, the dark background 
corresponds to the fluid phase and the light gray areas to the condensed domains at the 
interface [301-302]. 
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BAM is mounted in a trough and is composed by the optical components, namely a 
laser, the polarizers, lens and a charge-coupled device camera [298]. It also possesses a 
video camera that allows to record the monolayer by both film and pictures [297]. 
The BAM angle is determined using the Snell’s law (Equation 25): 
 tan  α  =  !!!!                                                                                                          (25)  
 
where α is the Brewster angle in radians, n1 the refractive index of air (≈ 1) and n2 the 
refractive index of water. Therefore, if a p-polarised light impinges at the air–water 
interface at the Brewster angle (53.1°), no light is reflected from the interface between the 
two media with different refractive indices (Figure 41). Therefore, at the mentioned angle 
of incidence, the introduction of a Langmuir monolayer at the air/water interface modifies 
the Brewster angle conditions, and light is reflected. The BAM images obtained are 
commonly digitised and filtered in order to reduce diffraction fringes caused by the 
coherent nature of the laser beam and finally processed to improve their quality [292]. 
 
 
 
 
 
 
 
Figure 41. Principle of Brewster Angle Microcopy. 
6. Polarization Modulation Infrared Reflection-Absorption 
Spectroscopy  
The first successful application of the IRRAS (infrared reflection absorption 
spectroscopy technique to the Langmuir monolayers was in 1985 [303]. A major difficulty 
addressed is the strong signal that arises from the liquid and vapor phases of water, that 
mask the vibrations of important vibrational groups, as the amide, specially important in 
the study of proteins and drugs with this chemical group [303]. In this regard, the PM-
α = 53.1° 
Air	  Monolayer	  Water	  
No	  Reflection	   Reflection	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IRRAS (polarization modulation infrared reflection absorption spectroscopy) developed by 
Baldez et al was developed [303].  PM-IRRAS is a more sensitive technique due to its 
combination with a polarization-modulation by means of a photoelastic modulator, which 
allows to minimize the signal of interferents as the water and carbon oxid [304]. 
 PM-IRRAS is associated with a trough, which must have an adequate size (≥ 6 
cm) in order to minimize the meniscus formation. The IRRAS equipment includes an 
adjustable incident infrared radiation that allows an illumination of the aqueous surface at 
a wide range of incident angles. The optical path must have a position for a high quality 
polarizer. Additionally, the entire setup must be enclosed and purged to keep the relative 
humidity levels low and constant. In addition, the PM-IRRAS uses a polarization 
modulation technique [303]. This technique is based in the mid-infrared radiation on the 
monolayers films, being a minor fraction (6%) of the light reflected from the molecular 
constituents of the surface. The data is generally presented as plots of reflectance–
absorbance versus wavenumber. The reflectance-absorbance is defined by the Equation 
26 [305]: 
-­‐log10(R/Ro)                                                                                                  (26)  
where R is the reflectivity of the film-covered surface and Ro is the reflectivity of the 
aqueous subphase. In addition, the incident light in a well-defined polarization state, 
either parallel (p-polarized) or perpendicular (s-polarized) to the plane of incidence, 
impinges onto the surface air-water at a previous defined angle of incidence, being the 
reflected light detected at an angle equal to the angle of incidence [305], which in the 
experiments of this thesis was set up to 80°. 
 IRRAS constitute a powerful in situ technique to study the interactions of drugs 
with lipids and proteins at the air-water interface, providing information concerning the 
changes in the molecular structure and orientation of the monolayer constituents caused 
by the studied drugs [305-306]. This versatile technique has a broad of application fields, 
including the determination of the ordered state of the monolayer, which includes the 
study of the lipid chain conformation and tilt as well as the study of the secondary 
structure of the proteins [305].  
 IRRAS measurements provide frequencies and intensities of molecular vibrations. 
Each chemical group possesses a certain frequency of vibration and for that reason may 
be identified and characterized (Table 2). Additionally, the frequency of the vibration of 
some groups is sensitive to the hydration (e.g. phosphate and carbonyl), the 
conformational order (e.g. methylene) as well as the secondary structure of the proteins 
(e.g. amide) [305]. The study of the phosphate (PO2−) and carbonyl (C=O) groups allows 
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to understand the interactions of a drug with the polar regions of the monolayer films. The 
PO2− symmetric stretch arises at ∼ 1090 cm-1, and is not sensitive to the hydration of the 
monolayer. The spectral region of 1190-1300 cm-1 contains the asymmetric PO2− 
stretching vibration, which is sensitive to the phosphate group hydration (i.e., H-bond 
formation). A lower wavenumber comprised in this range is indicative of a high hydration 
degree, being a higher wavenumber indicative of a less hydrated monolayer [305]. The 
same is also true for the carbonyl group (C=O) comprised in the range of 1710-1740 cm-1 
[305]. Therefore, a wavenumber near 1740 cm-1 corresponds to unhydrated C=0 bonds 
and 1720 cm− 1 arising from hydrated C=O bonds [305]. The decrease in the vibrational 
frequencies of the methylene group (CH2) is an indication of the increase of the 
conformational order of the acyl chains present in the monolayer. Therefore, the decrease 
in the asymmetric CH2 stretching frequency from approximately 2922.5 to 2917 cm− 1 with 
the monolayer compression provides information about the formation of all-trans 
conformation (characteristic of condensed monolayers) and the loss of gauche 
conformers (characteristic of expanded monolayers) [305],[307],[308]. The amide I band 
can give information concerning the secondary structure of the proteins and according to 
the band position allows the identification of β-turns (1662–1682 cm− 1), α-helices (1645–
1662 cm− 1), and β-sheets (1613–1637 cm− 1). If the band appears as two components: 
one at the β-sheet position and another as a shoulder at 1682–1710 cm− 1 it is indicative 
of an antiparallel β-sheet. The parallel β-sheet is predicted to a have higher frequency for 
the lower component [309-312]. The disorder of the random coils (unstructured) occurs at 
the same wavenumbers as of the α-helices (1637–1650 cm− 1), originating from the former 
broader and less intense bands compared to the α-helices [310-311],[313]. The amide II 
(1520-1560 cm-1) is also sensitive to the secondary structure of the proteins, being 
although less used or used as complementary information since it is less sensitive than 
the amide I [305]. Other chemical groups may be identified, being the above-mentioned 
groups the most common and the ones characterized during this thesis. In addition, the 
positive or negative sign of the bands indicates the orientation of the chemical groups, 
perpendicular or parallel, respectively with respect to the air/solution interface [314]. 
Additionally, the existence of identical or nearly identical chemical groups in the drug, lipid 
or protein may be overcomed by the use of isotope labels [305].  
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Table 2. Infrared vibration modes used for analysis of IRRAS spectra. 
 
 
7. UV-Vis Reflection Spectroscopy 
The UV-Vis (in the range of 250-700 nm) spectroscopy is an important tool to be 
applied to the monolayers when the studied drug is a chromophore and absorbs in the UV 
and/or visible radiation [315]. This technique permits to identify the presence of the drug in 
the monolayer and its amount during the monolayer compression, because the water 
subphase does not absorb in this spectral region and therefore does not interfere with the 
spectral analysis of the monolayer studied [316]. At normal incidence, the reflection 
increment from the air-water interface due to the presence of a Langmuir film can be given 
by the Equation 27 [292]: 
ΔR = A (Ri)1/2 + p2                              (27) 
where A is the reflectivity of the monolayer, Ri is the reflectivity of the water surface in the 
absence of the monolayer and p2 is the absorption of the monolayer. In addition, the shifts 
of the absorption maximum are correlated with the presence of aggregation at the 
interface [292]. 
Vibration Mode Wavenumber 
(cm-1) 
Comments 
CH2 symmetric strech 2849-2854 Qualitive indicator of the conformational order 
CH2 asymmetric strech 2916-2924 Qualitive indicator of the conformational order 
PO2- symmetric strech ∼ 1090  
PO2- asymmetric 
strech 
1220-1250 Frequency is sensitive to the hydration 
C=O (ester) strech 1710-1740 Frequency is sensitive to the hydration 
Amide I 1610-1690 Frequency is sensitive to secondary structure 
Amide II 1520-1560 Frequency is sensitive to secondary structure 
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The UV-Vis spectroscopy was performed in order to confirm the presence of the 
chromophore RFB at the air-water interface and in addition to quantify its amount during 
the compression and expansion of the monolayer [317]. 
 
8. Computer Simulations 
The scientific method has been brought to science in the 17th centuary by Galileo, 
being further refined by Francis Bacon. Traditionally, the scientific method involves an 
observation, a formulation of a hypothesis, the test of the hypothesis and the achievement 
of a conclusion or the refinement of the initial hypothesis. The computer models and 
simulation studies may be integrated into the scientific method to test ideas before the 
execution of the experiments or in the other hand, to corroborate the experimental results. 
Therefore, the computer simulations may be used as an intermediate tool in the scientific 
method [318]. 
During this thesis two major computational chemistry softwares were used, namely, 
HyperChem® and MarvinView from ChemAxon®. 
 HyperChem® is a versatile molecular modeler and editor that offers many types of 
molecular and quantum mechanics calculations. Several may be used, as the well known 
Monte Carlo simulations. In this thesis, was applied the molecular mechanism method to 
complement the experimental information that pointed to a strong interaction between 
RFB and the polar head groups of DPPC. The computer simulations pointed to the 
production of a inclusion complex between the drug RFB and the polar head groups of 
DPPC phospholipids, which corroborate the experimental results [319]. 
MarvinView from ChemAxon® is chemical viewer software for single and multiple 
chemical structures, queries and reactions . In this thesis it was used to predict the pKa, 
microespecies according to the pH, log P and log D of RFB and analogs [320].  
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Chapter IV 
Progress Beyond the State-of-the Art 
This chapter presents all the manuscripts that this thesis originated, namely: 
 
1 – Liposomes as drug delivery systems for the treatment of TB. 
 
2 – Molecular interaction of Rifabutin on model lung surfactant monolayers. 
 
3 – Interplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant 
membrane: a biophysical approach to disease. 
 
4 – Differential interactions of rifabutin with human and bacterial membranes: implication 
for its therapeutic and toxic effects. 
 
5 – Drug-membrane interaction studies applied to N'-acetyl-rifabutin. 
 
6 – Effects of a novel antimycobacterial compound on the biophysical properties of a 
pulmonary surfactant model membrane. 
 
7 – Evaluation of the structure-activity relationship of rifabutin and analogs: a drug-
membrane study. 
 
8 – The Influence of Rifabutin on Human and Bacterial Membrane Models: Implications for 
Its Mechanism of Action. 
 
9 – Interactions of N'-acetyl-rifabutin and N'-butanoyl-rifabutin with lipid bilayers: A 
synchrotron X-ray study. 
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1. Liposomes as drug delivery systems for the treatment 
of TB. 
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2. Molecular interaction of Rifabutin on model lung 
surfactant monolayers. 
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3. Interplay of mycolic acids, antimycobacterial 
compounds and pulmonary surfactant membrane: a 
biophysical approach to disease. 
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4. Differential interactions of rifabutin with human and 
bacterial membranes: implication for its therapeutic and 
toxic effects. 
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5. Drug-membrane interaction studies applied to N'-
acetyl-rifabutin. 
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6. Effects of a novel antimycobacterial compound on the 
biophysical properties of a pulmonary surfactant model 
membrane. 
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7. Evaluation of the structure-activity relationship of 
rifabutin and analogs: a drug-membrane study. 
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8. The Influence of Rifabutin on Human and Bacterial 
Membrane Models: Implications for Its Mechanism of 
Action. 
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9. Interactions of N'-acetyl-rifabutin and N'-butanoyl-
rifabutin with lipid bilayers: A synchrotron X-ray study. 
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Chapter V 
 
Conclusions 
 
The full picture of drug-membrane interactions is often neglected and underestimated, 
being the retrospective perspective beyond the biophysical studies an indubitable key to 
fully understand the mechanism of action and the side effects of the drugs, and 
consequently to develop more effective and safer medicines. The idea beyond the 
development of drugs considering only a specific target is overvalued and often leads to 
the screening of molecules that despite an optimal binding to the target (e.g. receptor, 
enzyme), will never reach the market due to the lack of pharmacokinetics properties or 
even the necessary efficacy to be useful in the clinical practice. In fact, it is undeniable 
that the drugs pass through the membranes, being questionable the harmless of the drug 
to the diverse biological membranes that cross along its track. Moreover, the perspective 
of the biological membranes as undamaged structures and merely passive barriers, while 
drug’s crossing may only be interpreted in terms of a reductionist perspective of a drug as 
a “magic bullet” that follows a certain trajectory in the direction of a specific target. In 
addition, the contact of the drugs with many different biological membranes goes along 
the destiny of a drug after its oral administration. In the particular case of RFB, from the 
circulating macrophage cells to the vessel endothelium, to the more complex absorption 
barriers and the bacterial membrane, until reach the target sites, the interaction with these 
membranes largely affects its pharmacokinetics properties. Moreover, investigating the 
phenomena occurring on the human and bacterial plasma membranes, as well as their 
different interaction with drugs under physiological conditions, is important to exploit the 
molecular basis of TB and to identify new potential therapeutic strategies [264]. In this 
context, the results of the drug-membrane interaction studies support differential 
interactions between the human and the bacterial membrane models. In addition, the 
mechanism by which this antibiotic permeates through the phospholipid bilayers seems to 
include an electrostatic adsorption at the interface region, followed by its permeation and 
induction of pronounced changes into the bacterial membrane biophysics. RFB also 
demonstrated to induce a phase separation in the bacterial membrane models, which 
might compromise the integrity of that membrane. On the other hand, RFB showed 
marked effects in the human membrane model, especially in the gel phases, which may 
be related to some adverse effects caused by its ability to interact with some of the most 
ordered membranes of the human body, causing uveitis and with the reaching to the 
stratum corneum, triggering the discoloration of the skin. The study of the drug-membrane 
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involving RFB and their analogs allowed to establish a relationship between the chemical 
structures of the antimycobacterial compound and their effects in the membranes. The 
correlation found may be useful in the development of new drugs with more favourable 
pharmacokinetics properties, since the knowledge about the influence of different 
structural interdependencies between the antimycobacterial compound’s chemical 
composition and the antimycobacterial compound’s expected effects is fundamental to the 
rational development of more effective drugs with less toxic effects. Therefore, the 
substitution with additional lipophilic groups in the secondary amine of the RFB’s analogs 
was responsible for more marked interactions with the biological membranes. This higher 
lipid-affinity seems to increase the access of the antibiotics to the cells where the bacteria 
is located and its entry into the extremely lipophilic mycobacterial membranes. On the 
other hand, since the toxic effects of this class of drugs are strongly influenced by their 
affinity to the biological membranes, the RFB analogs may exhibit more pronounced 
effects as the uveitis, discoloration of the skin and body fluids, being needed further 
studies to ensure their security before reaching the market. Nevertheless, the electrostatic 
interactions with the bacterial membrane are expected to be less pronounced than in the 
case of the lead compound (i.e. RFB). In fact, the affinity of RFB2 to the bacterial 
membrane model was proved to be less pronounced than in the case of RFB. This 
expected consequence is due to the above-mentioned effect of the substitution in a 
protonated group (secundary amine of the imidazole) that decreases the positively 
charged molecules able to interact by ionic bonds with the negatively charged 
phospholipids of the bacterial membrane. Nonetheless, both analogs seem to change the 
bacterial membrane curvature, promoting the formation of cubic phases that may 
contribute to the bacterial cell death through the production of pores in the membrane. 
Regarding the interest of the cubic phases in the lipid-based liquid crystalline materials as 
drug delivery systems, the lipid composition may be exploited to produce liposomes as 
drug delivery systems of RFB2 and RFB3.  
The study of the interaction of RFB with the PS membrane models was useful to 
understand the accumulation of the drugs in the main organ affected by the TB disease 
drug, the lungs. In fact, the accumulation of the drug seems to be related with its 
distribution at the PS lipid level. Indeed, an inclusion complex formed by RFB and the 
polar head groups of the phospholipids was reported. In addition, the inclusion complex 
restricted to the polar head groups of the phospholipids prevents the penetration of the 
drug into the hydrophobic tails, leading to a possible disruption of the monolayer with 
toxicological effects to the normal function of the lungs. The interaction of RFB2 with the 
PS also revealed also a strong interaction with the phospholipid head groups associated 
with a decrease of the phospholipid packing, which may be an advantage in the future 
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development of liposomal controlled release formulations exploiting the inhalatory delivery 
of this antimycobacterial compound directly to lungs. Therefore, the encapsulation of 
RFB2 in liposomes made of the main phospholipid present in the PS featured a faster 
opening and release of the liposomes content, which is a major drawback in the use of 
liposomes as drug delivery systems for the inhalatory route.  
Furthermore the protecting effect of RFB and RFB2, by avoiding the surfactant 
dysfunction promoted by compressibility changes induced by the bacterial lipids (i.e. MAs), 
was proven. At the dynamic inspiratory surface tension (with more biological relevance), 
high amounts of MAs decrease the order of the lipid monolayer. Moreover, it was proven 
that the amount of MAs might play a critical role in the initial access of the bacteria to their 
targets (AMs). In the presence of higher amounts of MAs, RFB and RFB2 increase the 
phospholipid packing and, therefore, the order of the lipid surfactant monolayer. In 
addition, the hysteresis of the PS monolayer when both antimycobacterial compounds 
and MAs are present does not increase in comparison to the hysteresis of the PS 
monolayer when MAs are present in the absence of the antimycobacterial compounds, 
suggesting that the RFB and RFB2 may reduce the amount of bacteria that is able to 
reach the AMs and the bloodstream, by acting as ordering agents.  
In summary, this thesis gave a contribution regarding the drug-membrane interactions, 
allowing to obtain a deeper understanding beyond the therapeutic and toxic effects of 
RFB and analogs, which may be useful in the design of new drugs with a more limited 
range of toxicity. 
1. Limitations of the Experimental Studies  
One of the major limitations pointed to the biophysical studies of drug-membrane 
interactions is generally the lack of all the constituents generally present in the 
membranes (e.g. proteins, sugars) and/or the lipid composition chosen. However, the 
biophysical studies should be interpreted in the most cases as retrospectives studies. 
Thus, in the presence of a certain phenomena not fully explained by the conventional 
point of view of a drug’s mechanism of action (i.e. drug that has a specific target and 
commonly a protein), the biophysical studies may help to get a higher knowledge about 
the mechanism of action, using for that simple but reliable membrane models. It is 
important to report that the simplification and therefore a complete control of so complex 
structures is critical to understand the interactions at the molecular level. For instance, in 
the case of the inclusion complex formed by the drug and the main lipids of the PS, it 
would be impossible to described it using the same techniques with a more complex PS 
membrane model (e.g. Curosurf®). In addition, the concentrations used are in most cases 
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much higher in comparison with the achieved therapeutic plasmatic concentration of RFB 
(can reach until ~1 µM depending of several factors). This is obviously related with the 
sensibility of the techniques used but more important with the interest of study the high 
concentrations acumulated in the tissues, much more higher than the plasmatic 
concentration. In fact, the plasma concentrations of RFB do not reflect the much higher 
concentrations that can be achieved in the infected cells and in organs as the lungs, 
where the levels are six times higher when compared with the plasma concentrations. 
 
2. Future Perspectives 
At the end of the thesis is undeniable that the obtained results obtained bring new 
answers and hypothesis that may lead to future studies, involving:  
- Membrane models of different composition. In fact, in a first approach the lipid 
composition should be chosen as the most simplistic possible (although reliable), and then 
must be successively optimized and approximated to the physiological. The lipid 
composition has been revealed as a critical factor to the drug-membrane interactions. For 
instance, RFB interacts differently according to the plasma membrane model chosen (1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) vs. (egg-phosphocholine) EPC:CHOL). 
Nevertheless, this approach allowed us to understand how the drug interacts with the 
phospholipids and the role of CHOL in the different interactions. In addition, the interaction 
is dependent of the chosen PS membrane model, DPPC, DPPC:DPPC:DPPG or a natural 
PS (i.e. Curosurf®). The former model is the one with most biological relevance (regarding 
the presence of proteins and the presence of other lipids that are present in the PS). 
Other PS membrane models may be used with a more complex composition, more similar 
to the human PS (for instance Curosurf® does not have hydrophilic proteins). In addition, 
to mimic human plasma membrane models, proteins may be add, as well as mixtures of 
CHOL, sphingomyelin to mimic the lipid rafts. To better mimic the bacterium membrane, 
lipids as CL and PI should be used. In addition, the lipid envelop of the MTb also has in its 
composition the TDM and therefore it should be used in substitution of the MAs.  
- Studies with other experimental conditions. In fact, all the studies were made at the 
physiological pH (i.e. 7.4). However, it is well know that when the MTb is inside the AMs, 
the pH decreases to values that depend on the macrophage activation (6.2 and 5); being 
the studies of the drug interactions with membrane models at a lower pH of interest, in 
order to understand if the drug interacts differently with the membrane according to the 
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pH. Moreover, RFB is a drug that eradicates the Helicobacter pylori located in the 
stomach, being non toxic to the stomach layer and therefore, lower pH’s that mimic the 
acid pH of the stomach (range pH 2-5) may be tested. 
- This study could be extended to other anti-TB drugs as other ryfamicins (e.g. RIF) and 
other anti-TB drugs (e.g. isoniazid), for which the mechanism of action still remains not 
fully understood. 
- Application of other biophysical techniques to study drug-membrane interactions. 
Namely, the nuclear magnetic resonance (NMR) and neutron diffraction to study the 
location of the drugs within the membranes without the necessity of using probes. 
Techniques, such as the atomic force microscopy (AFM) allow to visualize the supported 
lipid bilayers. Techniques such as Grazing incidence X-ray diffraction (GIXD) and X-ray 
reflectivity may be applied to the monolayers in order to study, respectively, the changes 
of the phospholipids molecular order induced by the drugs or other lipids (e.g. MAs) and to 
study the influence in the structure of the monolayer. 
- These biophysical studies may be interpreted as the preliminary studies to the further 
design and development of an innovative of a nano-carrier lipid based (e.g. liposomes and 
lipid nanoparticles) for targeted delivery of RFB and analogs. Indeed, the present thesis 
seeks to deepen the scientific knowledge about the biophysics underlying drug-membrane 
interactions, in order to chose lipid based nano-carriers systems with a rational 
composition selection based in the biophysical properties observed for the drug-
membrane interactions. The chosen membrane models allow us to predict the type of the 
interactions of RFB and analogs with the drug delivery systems (e.g. liposomes and lipid 
nanoparticles), which could be critical for efficient drug delivery lipid-based systems. For 
instance, to obtain a significant incorporation of RFB and analogs and regarding their 
interactions, liposomes with several lipid bilayers  (MLVs instead LUVs) should allow a 
higher incorporation. In addition, lipids with negative charge may be considered for 
inclusion in the formulation, avoiding mixtures that seem to permit the release of the drug 
(i.e. EPC:CHOL 4:1 molar ratio). Nevertheless, the release may be desirable in the 
delivery of the liposomes by the inhalatory route. Moreover, the analogs induce isotropic 
phases (i.e. cubic phases) in the lipid nano-carrier and this might be exploited to a 
controlled release formulation of these molecules. 
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